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As currently available chronic pain medication is associated with undesirable side effects and 
suboptimal efficacy, the improvement of treatment options is a major task in the pain research 
community. The basis for the latter is an advanced understanding of the molecular mechanisms 
underlying chronic pain states. The approach to target molecules that are specifically involved in the 
pathological form of pain is highly important in order to maintain an individual’s ability to process 
acute nociceptive pain. Such a strategy ideally allows for novel drug target identification, and thereby 
decreased side effects and enhanced therapeutic outcomes. Here, an uncharacterized mitochondrial 
transmembrane protein (TM) was investigated with regard to its role in chronic inflammatory and 
neuropathic pain. In a previous quantitative proteomics study, TM and other mitochondrial proteins 
showed differential expression in two mouse models of chronic pain. This finding was in line with the 
growing evidence for the connection between mitochondrial dysfunction and diverse chronic pain 
conditions.  
TM was characterized in vivo by generating knock out (KO) mice with the CRISPR/Cas9 technology. 
Effective gene ablation was confirmed by, genomic sequencing, quantitative RT-PCR and in situ 
hybridization. Neuropathic pain was induced by a spared nerve injury (SNI-model) and the 
intraplantar injection of CFA (Complete Freund’s Adjuvant) that causes inflammatory pain. Sham 
operated/vehicle injected mice served as controls. Subsequently, a battery of behavioral paradigms 
including measures of stimulus-evoked and spontaneous pain was performed. Strikingly, a specific 
attenuation of mechanical hypersensitivity upon induction of inflammatory pain and in the initial 
stage of neuropathic pain (7 days post surgery, marked by pronounced inflammation) was shown in 
TM KO mice. However, later neuropathic pain phases were not affected. Moreover, other 
investigated pain modalities such as heat hypersensitivity, NEP and movement-evoked pain were 
unaltered in TM-deficient mice. Besides, several in vitro techniques were applied to study the 
molecular basis for the behavioral phenotype. They revealed altered mRNA levels of several 
prototypic inflammatory mediators and components implicated in mitochondrial function in dorsal 
root ganglia (DRG) and sciatic nerves (SN) of TM KO mice. Mitochondrial dysfunction and potential 
alteration of neuronal excitability could not be approved with the applied methods. However, 
decreased activation of a specific nociceptor subpopulation was shown in sensory neurons upon TM 
ablation, which could be rescued by application of the cytokine TNFα (downregulated mRNA level).  
Further research is needed to understand the molecular mechanism underlying the specific 
alleviation of mechanical hypersensitivity during the early inflammatory stage of neuropathic pain 
and CFA-evoked inflammatory pain in TM KO mice. Yet, these results propose a novel and pivotal 
implication for TM in modality-specific pain signaling. 
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1. INTRODUCTION 
1.1 Somatosensation and Pain             
The skin is the largest sensory organ in our body. It protects us and constitutes the basis for 
somatosensation, as it is innervated by peripheral axons of pseudo-unipolar primary sensory 
neurons. These neurons have their somata located within dorsal root ganglia (DRG, trunk and limb 
innervation; Figure 1), trigeminal ganglia (TG, cephalic innervation) or nodose and jugular ganglia 
(vagal innervation of viscera and head) (Kollarik et al., 2010). They communicate to the central 
nervous system (CNS) via central axons projecting to the spinal cord (for DRG neurons; Figure 1) or 
the trigeminal subnucleus caudalis (for TG neurons) (Basbaum et al., 2009; Dubin and Patapoutian, 
2010). A high threshold subpopulation of primary sensory neurons, the so called nociceptors, are 
able to detect extreme thermal, mechanical and chemical signals (e.g. a hot object or an intense 
pinch). Hence, nociceptors are able to detect potentially damaging noxious stimuli and thereby fulfill 
their most important function, namely the guarding of our physical integrity (Woolf and Ma, 2007). 
This significance for nociceptive signaling is demonstrated by individuals suffering from the 
congenital insensitivity to pain (CIP) (Cox et al., 2006; Indo, 2001), which results in self-mutilation by 
repeated unnoticed injuries. However, if healthy individuals are harmed the healing process is 
accompanied by hypersensitivity of the affected tissue in order to promote guarding (e.g. sunburn). 
As a consequence usually innocuous stimuli as light touch elicit pain (allodynia) or painful stimuli are 
perceived more intensely (hyperalgesia). 
Moreover, noxious stimuli detectors are divided into subclasses that mediate the “first” well-
localized and the “second” poorly-localized pain. The former is conducted by thinly-myelinated Aδ 
fibers that possess a relatively slow conduction velocity (CV) of 12-30 m/s, a medium diameter of 2-5 
µm and a cell body size of 30-40 µm. The latter is conveyed via unmyelinated slow conducting C 
afferents (CV 0.5–2 m/s) that have thin axons of 0.4-1.2 µm and small somata (< 25 µm). Light touch, 
i.e. innocuous mechanical stimulation, on the other hand, is rapidly transmitted (CV of 70-130 m/s) 
by myelinated large caliber (5-20 µm) Aβ sensory neurons (cell bodies > 40 µm) (Figure 1). 
Furthermore, Aδ nociceptors project to the spinal dorsal horn lamina I as well as to lamina V, 
whereas C fibers synapse to second order neurons in the superficial laminae I and II. By contrast, low 
threshold Aβ afferents project to the deep laminae III, IV and V within the dorsal horn of the spinal 
cord. The spinal dorsal horn is an important hub of the pain axis as it connects the periphery to the 
brain. Inputs from peripheral nociceptors, local interneurons and descending projections are 
integrated and processed signals are transmitted to the brain pain network (Todd, 2010; Figure 1). 
(Basbaum et al., 2009; Bourinet et al., 2014; Costigan et al., 2009; Patapoutian et al., 2009). 




Figure 1: The Ascending Pain Pathway  
Primary sensory neurons are composed of somata located in dorsal root ganglia (DRG), in addition to 
peripherally and centrally projecting axons. These neurons can be divided into several subtypes such as small 
non-myelinated C fibers and medium-sized slightly myelinated Aδ fibers that are primarily responsible for 
thermosensation and nociception. Large-diameter Aβ fibers mainly convey touch perception (neuronal 
subtypes are illustrated in the DRG magnification). Upon noxious stimulation of the sensory nerve ending the 
signal is propagated as an action potential along the peripheral axon that synapse to second order spinal dorsal 
horn neurons. In the dorsal horn the sensory information is integrated and sent to the thalamus and higher 
cortical brain structures where the sensation of pain is generated. Modified from (Bourinet et al., 2014). 
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1.2 The Molecular Basis for Nociception 
The expression of specialized transducer ion channel receptors, mainly transient receptor potential 
(TRP) channels by high threshold primary sensory neurons constitutes the molecular basis for 
nociception. Channels like the transient receptor potential vanilloid receptor 1 (TRPV1) and transient 
receptor potential ankyrin 1 (TRPA1) are tuned to respond to polymodal stimuli and therefore allow 
nociceptors the reaction to excessive thermal, chemical or mechanical stimuli (Dhaka et al., 2006). 
Sodium and calcium influx through these channels transform stimuli into spreading membrane 
depolarizations, propagating action potentials to higher brain centers enabled via the spinal cord 
(Talavera et al., 2008). The involvement of TRP channels in thermosensation and pain was first 
suggested in 1997 by Caterina and colleagues. It was found that TRPV1 is activated by capsaicin 
(active ingredient of chilli peppers) as well as by noxious heat (> 43°C), spider toxins and is 
modulated by low pH (a common effect of inflammation) (Caterina et al., 1997; Siemens et al., 2006). 
It is expressed in specific subsets of C and Aδ nociceptors that produce burning pain when they are 
depolarized during channel activation (Caterina et al., 1997). On the other hand, TRPA1 is activated 
by environmental irritants and a number of pungent chemicals found in food like isothiocyanates 
(mustard, horseradish), allicin (garlic) and cinnamaldehyde (cinnamon), excluding capsaicin (Bandell 
et al., 2004; Bautista et al., 2005; Jordt et al., 2004; Macpherson et al., 2005, 2007; Story et al., 
2003a). Furthermore, it is usually coexpressed with TRPV1 in unmyelinated C and slightly myelinated 
Aδ primary afferents (Nagata et al., 2005; Story et al., 2003a). (Basbaum et al., 2009; Bourinet et al., 
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1.3 Pathophysiological Pain 
“Pain is a more terrible lord of mankind than even death itself” (Albert Schweitzer, 1931). This 
statement refers to the all-consuming excruciating sensation of pain, which has lost its protective 
function. It is considered as major clinical problem and affects around 20 % of the population (Breivik 
et al., 2006, 2013; Steglitz et al., 2012). Other than acute, nociceptive pain, persistent pain states do 
not seem to fulfill a useful physiological function (Hehn et al., 2012). Pain and excessive reactions to 
noxious and innocuous stimuli are evoked by long-lasting alterations in the nociceptive circuitry 
caused by inflammation, tissue, and nerve injury (Basbaum et al., 2009; Hucho and Levine, 2007).  
 
1.3.1 Inflammatory Pain 
Acute inflammation is a protective response characterized by rubor (redness), calor (increased heat), 
tumor (swelling), dolor (pain), and function laesa (loss of function). Its function is the elimination of 
the primary cause of injury and the induction of tissue repair. (Ji et al., 2016). Other than acute 
inflammation, chronic inflammation is often detrimental, causing a number of diseases such as 
rheumatoid arthritis, periodontitis, atherosclerosis, and even cancer (Ji et al., 2014). Various rodent 
models of chronic inflammatory pain are used at the level of the skin (e.g. intraplantar injection of 
CFA or carrageenan), the gut (e.g. dextran-sodium sulfate (DSS)-induced colitis) or the knee joint 
(CFA monoarthritis model). All models share the characteristic of primary afferent neuron 
sensitization due to altered ion channel function (among other factors) which can be assessed as 
allodynia and hyperalgesia, respectively. (Bourinet et al., 2014). Given the tremendous importance of 
TRP channels in somatosensation, their differential expression is often associated with neuropathic 
and inflammatory pain (Salat et al., 2013). The essentiality of these channels in sensitization of the 
afferent pain pathway was confirmed by their regulation via pro inflammatory signaling molecules 
like chemokines, growth factors, serotonin, bradykinin, prostaglandins and proteases (for review Vay 
et al., 2012). Moreover, chronic pain syndromes can be caused and preserved in the periphery and/ 
or the CNS and are not only physiologically but also psychologically debilitating which might 
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1.3.2 Neuropathic Pain 
Neurotoxic chemicals, infection, tumor growth, diabetes or nerve trauma cause lesions to the 
peripheral nervous system (PNS) that result in peripheral neuropathic pain. A number of 
pathophysiological alteration within the PNS and CNS are involved in this process (Dworkin et al., 
2003; Woolf and Mannion, 1999). Moreover, stroke, multiple sclerosis or spinal cord injury are the 
most common causes for central neuropathic pain (Ducreux et al., 2006). The neural damage and the 
primary disease it is caused from are the initiators of the essential neuropathic pain feature that is 
the manifestation of maladaptive plasticity in the nervous system (Costigan et al., 2009). These 
changes in the nerve properties often lead to increased spontaneous firing or alterations in their 
neurotransmitter properties or conduction (Basbaum et al., 2009). Spontaneous pain in the absence 
of an identifiable stimulus is a major characteristic of neuropathic pain which originates as a 
consequence of ectopic action potential formation within the nociceptive pathways. The ectopic 
activity seen in peripheral neuropathic pain arises in primary sensory neurons. Upon peripheral nerve 
injury, spontaneous activity is formed at various sites, including the site of tissue damage (neuroma), 
DRG soma (Amir et al., 2005) as well as adjacent unaffected afferents (Wu et al., 2002). The 
formation of spontaneous pain can be based on ectopic activity in low-threshold large myelinated 
afferents (Campbell et al., 1988) and from nociceptors (Bostock et al., 2005) caused by altered 
connectivity in the spinal cord and central sensitization (Woolf et al., 1992). The latter refers to the 
mechanism by which hyperexcitability within the CNS is established causing amplified processing of 
nociceptive signals that influences the affective and emotional facets of pain (Woolf, 1983; Woolf 
and Salter, 2000). Structures involved in the emotional aspects of pain are the anterior cingulate 
gyrus, amygdala, and prefrontal cortex, respectively (Fu et al., 2008; Pedersen et al., 2007). These 
might serve as basis for long-term mood and cognitive alterations that are learned and maintained 
(e.g. addictive and conditioned fear behavior) (Costigan et al., 2009).         
Two processes among numerous others that are implicated in central sensitization are alteration in 
glutamatergic neurotransmission and disinhibition (loss of tonic inhibitory controls) (Basbaum et al., 
2009). Nociceptive pain is signaled via glutamate release from central axons of nociceptors causing 
excitatory postsynaptic currents (EPSCs) in second order neurons within the dorsal horn. This is 
primarily caused by stimulation of postsynaptic subtypes (kainite and AMPA) of ionotropic glutamate 
receptors. Action potential generation and transmission of pain signals to higher order neurons will 
be ultimately caused by the summation of subthreshold EPSCs in the postsynaptic neuron. Under 
physiological conditions, the NMDA subtype of the glutamate channel is quiescent, whereas injury 
results in enhanced neurotransmitter release from nociceptors that will trigger silent NMDA 
receptors. The resulting elevated calcium influx can strengthen the synaptic connection of dorsal 
horn pain transmission neurons and nociceptors that consequently will amplify responses to noxious 
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stimuli (Basbaum et al., 2009). Glycinergic or GABAergic inhibitory interneurons are tightly packed 
within the superficial dorsal horn and provide the basis for the gate control theory of pain that 
suppose that disinhibition of these inhibitory interneurons would result in enhanced pain (Melzack 
and Wall, 1965). This loss of interneuron function increases spinal cord output as for NMDA-
mediated central sensitization in response to noxious and innoxious stimulation, contributing to 
mechanical allodynia (Keller et al., 2007; Torsney and Macdermott, 2006). Besides, enhanced 
intrinsic excitability of second order neurons seems to be the cause for spontaneous pain upon spinal 
cord trauma (Balasubramanyan et al., 2006; Hains and Waxman, 2007). The solid inhibitory effect of 
nonselective sodium channels blockers used as local anesthetics indicates the contribution of 
voltage-gated sodium channels to the formation of ectopic activity (Sheets et al., 2008). Several 
sodium channels that are sensitive or resistant to tetrodotoxin (TTX) (sodium channel blocker) are 
expressed by DRG neurons (Fukuoka et al., 2008). (Basbaum et al., 2009; Bourinet et al., 2014; 
Costigan et al., 2009; Ellis and Bennett, 2013). 
1.3.2.1 Neuropathic Pain Models 
 
In order to investigate the maladaptive plasticity evoked by neural injury, a number of rodent 
preclinical neuropathic pain models have been developed (Barrot, 2012). These models exhibit 
peripheral nerve injuries commonly affecting the sciatic nerve induced by compression, ligatures or 
transection (SNI-model) (Bennett, 1988; Decosterd and Woolf, 2000; Kim and Chung, 1992; Seltzer et 
al., 1990). Moreover, animal models of neuropathic pain are used that display metabolic disorders 
such as type 1 or 2 diabetes (Courteix, 1993; Latham et al., 2009) or that are induced by the 
administration of toxic components (e.g. anti HIV therapy and chemotherapy treatments) (Aley et al., 
1996; Descoeur et al., 2011; Joseph et al., 2004, 2009; Ling et al., 2007; Ta et al., 2009). The etiology 
assessed in neuropathic pain models evoked by toxic chemotherapy drugs is notably similar to what 
is observed in the clinic. Moreover, neuropathic pain conditions as well as inflammatory pain give 
rise to allodynia and hyperalgesia. Those phenomena are commonly assessed in chronic pain mouse 
models. The described infiltration of immune cells and the secretion of mediators within the nerve 
trunk are well characterized in a number of peripheral nerve injury animal models. Additionally, 
several models of neuropathic pain (including chemotherapy induced neuropathy) reveal 
inflammatory processes (Nishida et al., 2008; Peters et al., 2007). Moreover, pro inflammatory 
cytokines are involved in the genesis of diabetic neuropathy (Fornoni et al., 2008; Luis-Rodríguez et 
al., 2012; Rivero et al., 2009). (Basbaum et al., 2009; Bourinet et al., 2014; Costigan et al., 2009; Ellis 
and Bennett, 2013). 
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1.3.2.2 Neuron-Immune Cell Interaction upon Peripheral Injury 
 
Peripheral sensitization is commonly caused by inflammation-associated alterations in the chemical 
environment of the nerve fiber (Woolf and Ma, 2007). Tissue injury often involves the accumulation 
of endogenous mediators secreted from nociceptors and activated immune cells that reside within or 
infiltrate the damaged area. These mediators are known as the “inflammatory soup” and represent a 
broad range of signaling molecules such as peptides and neurotransmitters (calcitonin gene-related 
peptide (CGRP), substance P, bradykinin), eicosinoids and cognate lipids (endocannabinoids, 
thromboxanes, leukotrienes and prostaglandins), in addition to extracellular protons and proteases. 
Notably, one or more cell-surface receptors that are able to recognize and respond to these pro- 
algesic or pro-inflammatory factors are expressed by nociceptors. This interplay is responsible for 
increased nerve fiber excitability that results in enhanced sensitivity to touch or temperature. 
(Basbaum et al., 2009). More precisely, upon nerve damage, resident mast cells degranulate which 
results in the release of inflammatory factors (e.g. serotonin, histamine, nerve growth factor (NGF)) 
that sensitize nociceptors and recruit the first infiltrating immune cells, namely neutrophils (Kim and 
Moalem-Taylor, 2011; Perkins and Tracey, 2000; Smith et al., 2008; Zuo et al., 2003; Figure 2). 
Neutrophils then again secrete factors capable of sensitizing nociceptors and attract T cells and 
macrophages to the site of injury (Kumar and Sharma, 2010; Moalem et al., 2004). Recruited 
macrophages join the resident macrophages and together with Schwann cells promote the Wallerian 
degeneration of axotomized nerve fibers distal to the damaged nerve (Figure 2). Moreover, they 
release a great number of pro- inflammatory chemokines and cytokines as well as lipid mediators 
(Nathan, 1987; Figure 2). In the majority of cases, macrophages evoke pain by the secretion of pro-
inflammatory mediators like TNFα and IL1-β (Zelenka et al., 2005; Figure 2), causing increased pain 
transduction and conduction by ion channel modulation (e.g. TRPV1, TRPA1 and Nav1.7-1.9) 
(Basbaum et al., 2009; Ji et al., 2014). In addition, related to their functional state, macrophages can 
have pro-inflammatory M1-like or anti-inflammatory M2-like phenotypes which are differentially 
involved in the induction or resolution of pain (Ji et al., 2016). T cells can also have different 
phenotypes also characterized by the secretion of pro- or anti- inflammatory cytokines (type 1 or 2 
helper T cells (TH1 and TH2)). TH1 cells release pro-inflammatory cytokines (e.g. TNFα, IL-1β and IL-
17) that facilitates neuropathic pain, whereas TH2 cells inhibit it by secretion of anti-inflammatory 
cytokines (e.g. IL-10, IL-4 and IL-13) (Moalem et al., 2004; Palmer and Weaver, 2009). (Basbaum et 








Figure 2: Immune and Glial Cell Reactions at Site of Nerve Injury  
Peripheral nerve injury recruits and activates immune cells at the site of the damaged nerve. Mast cells, 
macrophages and T cells infiltrate the injured nerve and distribute around the distal fiber stumps. Signaling 
molecules such as CGRP, substance P, and bradykinin are released from the proximal fiber stumps and evoke 
hyperemia and swelling, supporting further invasion of T cells and monocytes. Chemokines (e.g. CCl2) engage 
and direct monocytes to the injured area. Mast cells and macrophages set prostaglandins and cytokines (e.g. 
TNFα and IL-1β) free. TNFα has an autocrine impact on macrophages that is conveyed via the tumor necrosis 
factor receptor 1 (TNFR1) stimulation and increases cytokine synthesis and release. This prototypic 
inflammatory mediator also facilitates additional infiltration of macrophages. Schwann cell proliferation and 
dedifferentiation follows with subsequent formation of bands of Büngner, that are used as guiding tubes for 
regenerating axonal processes. Adapted from (Scholz and Woolf, 2007). 
 
Moreover, satellite cells, T cells and macrophages drive an immune response in the DRG after 
peripheral nerve damage, similar to that observed in the injured nerve (Figure 3). It was shown that 
neutrophils invade the ipsilateral DRG upon nerve damage between 7 and 14 days post-surgery 
(injury dependent) which takes place at lower levels and starts much later than observed peripherally 
(Morin et al., 2007; Smith et al., 2008). Significant T cell infiltration to the ipsilateral DRG is also 
induced after peripheral nerve damage (around 7 days post injury) (Hu et al., 2007; Hu and 
McLachlan, 2002; Smith et al., 2008). This is in line with the upregulation of IL-10, TNFα, IL-1β and 
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several chemokines (e.g. CCl2) (Jung et al., 2008; Kiguchi et al., 2010; Sun et al., 2006) in the DRG 
upon injury (Levin et al., 2008; Üçeyler and Sommer, 2008). Those chemokines and cytokines act on 
their receptors on DRG neurons and evoke ectopic discharges and elevated primary afferent input to 
the spinal dorsal horn by coupling to TRP and sodium channels (Ren and Dubner, 2010).  
Furthermore, peripheral nerve trauma causes the activation of spinal microglia that dominates the 
early CNS glial response (Figure 3), followed by astrocyte activation and proliferation. Microglia 
(resident mononuclear CNS phagocytes) and macrophages (derived from circulating monocytes) 
share a number of similarities in regard to their functional and immunological properties (Streit, 
2002). (Scholz and Woolf, 2007). Given the resemblance between macrophages and microglia, it is 
not surprising that the latter form dense clusters around the somata of damaged motor neurons of 
the spinal ventral horn as macrophages do in DRG around medium to large diameter neurons (peak 7 
days post nerve damage) (Hu et al., 2007; Hu and McLachlan, 2002; Smith et al., 2008). Moreover, a 
massive microglial recruitment and activation (peak 7 days post injury) is found in the dorsal horn 
adjacent to the central terminals of injured sensory nerve terminals (Beggs and Salter, 2007; 
Marchand et al., 2005; Tsuda et al., 2005; Watkins and Maier, 2015; Figure 3). Their activation is 
accompanied by upregulation of microglial markers such as IBA1 and CD11b in the spinal cord (Ji et 
al., 2016).  
The signals responsible for microglial recruitment include CSF1, ATP, chemokines (CCl2 and CX3CL1), 
and proteases that can arise from activated or injured sensory neurons. The enhanced expression of 
the receptors for ATP, CX3CL1 and CCl2 (P2X7, P2X4, P2Y12, CX3CR1 and CCR2) on spinal microglial 
takes place in parallel upon nerve damage (Abbadie et al., 2003; Grace et al., 2014; Ji et al., 2013). 
The receptor activation converges on an intracellular signaling cascade in which the phosphorylation 
of p38 mitogen activated protein (MAP) kinase is implicated. MAP phosphorylation causes elevated 
production and release of cytokines (TNFα, IL-1β, IL-18), and brain-derived growth factor (BDNF), in 
addition to enhanced cyclooxygenase (COX) expression and subsequent prostaglandin E2 synthesis 
(Coull et al., 2005). The fine-tuning of both inhibitory and excitatory synaptic transmission by these 
neuromodulators follows, which then increases pain signal transmission to the brain. A number of 
members of the Toll-like receptors (TLRs) family also play a role in microglia activation upon nerve 
injury. They are transmembrane signaling proteins expressed by glial and peripheral immune cells 
(Kim et al., 2007; Tanga et al., 2005).  
Besides, Sorge and colleagues suggested that spinal microglia signaling is sex dependent. Reduced 
neuropathic pain could be achieved by microglial signaling inhibitors like p38 and minocycline 
inhibitors primarily in male mice, with little to no effect in female mice as pain signaling seems to be 
mediated by spinal T cells (Sorge et al., 2015). Astrocyte contribution to central sensitization is less 
defined. These glial cells are unquestionable induced in the spinal cord following nerve or tissue 
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injury (for review Ren and Dubner, 2010), but other than microglia their activation is usually delayed 
and lasts much longer (up to several months) (Basbaum et al., 2009). (Basbaum et al., 2009; Bourinet 
et al., 2014; Costigan et al., 2009; Ellis and Bennett, 2013). 
 
 
Figure 3: Immune and Glial Cell Reactions in DRG & Spinal Cord upon Nerve Injury 
A peripheral nerve lesion results in the recruitment and activation of immune cells in the DRG and spinal cord. 
Top, some T cells and macrophages are present in the DRG before nerve damage. This number enhances 
dramatically upon injury. Additionally, macrophages are moving in the sheath that is formed by satellite cells 
around the soma of primary sensory neurons. Satellite cells can be considered as peripheral counterpart of 
astroglia, because they trophically support primary sensory neurons and share some astroglial markers (e.g. 
glial fibrillary protein (GFAP)), respectively. They proliferate upon injury and increase GFAP expression. Bottom, 
dense bundles of microglia appear after a nerve lesion in the ventral spinal horn around somata of motor 
neurons. Besides, extensive activation of microglia takes place in the projection areas of the central terminals 
of impaired primary afferents in the spinal dorsal horn. Adapted from (Scholz and Woolf, 2007). 
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1.3 Mitochondrial Dysfunction in Chronic Pain   
Mitochondria are present in all nucleated eukaryotic cells and in addition to their central role in ATP 
synthesis, they are responsible for several cellular processes, such as apoptosis, calcium homeostasis 
and iron-sulfur cluster biogenesis (Duchen, 2000; Stehling and Lill, 2013). These organelles have an 
outer and an inner membrane that surround the intermembrane space (IMS) and the matrix. The 
cristae are formed by tubular invaginations of the inner mitochondrial membrane and host the 
electron transport chain (ETC) complexes. NADH or FADH2 are the electron supplies for the four ETC 
complexes in the inner mitochondrial membrane. The electrons are used as energy to produce a 
proton gradient across the membrane that drives ATP generation by the ATP synthase (also known as 
complex V). The redox systems of these complexes pass the electrons and ultimately, transfer them 
to molecular oxygen (complex IV). Hence, the ETC uses the energy of the oxyhydrogen reaction 
indirectly for ATP synthesis. (Dudek et al., 2013). Proteomics analysis suggested that mitochondria 
contain around 1500 different proteins in mammals and around 1000 different proteins in yeast 
(Pagliarini et al., 2008; Reinders et al., 2006; Sickmann et al., 2003). The ATP synthase as well as 
several ETC complexes are composed of subunits of dual genetic origin. Mitochondrial DNA (mtDNA) 
encodes 7 ETC subunits of complexes III-V in Saccharomyces cerevisiae, whereas 13 subunits of 
complexes I and III-V are mitochondrial encoded in humans. (Mick et al., 2012; Sickmann et al., 
2003). However, ETC subunits are mainly nuclear encoded genes that are synthesized as precursor 
forms on cytosolic ribosomes and subsequently transported into the organelle. This process takes 
place by the translocase of the outer membrane (TOM) and translocase of the inner membrane (TIM) 
import machineries (Schmidt et al., 2010; Vögtle et al., 2009). In order to be targeted to 
mitochondria and be sorted to distinct subcompartments, precursor proteins require specific import 
signals (signal peptide) within their sequence. The commonly found mitochondrial import signal is an 
N-terminal extension known as presequence or signal peptide. This signal peptide is an amphipathic 
α-helical segment with a net positive charge and reveals a length of 15-55 amino acids (Vögtle et al., 
2009). These signal peptides are usually removed proteolytically after import by the mitochondrial 
processing peptidase and other proteases (Mossmann et al., 2012; Taylor et al., 2001).         
Moreover, the crucial role of mitochondria in terms of ATP production, ROS formation and calcium 
buffering, specifically in rodent sensory neurons, was shown by Flatters and colleagues (Flatters, 
2015). Given their implication in crucial cellular processes it is not surprising, that mitochondrial 
dysfunction is involved in diseases such as neurological disorders (e.g. Alzheimer’s, Parkinson’s, and 
Huntington’s disease) (Abeti and Abramov, 2015; Hroudová and Singh, 2014; Pinto et al., 2012). The 
role of mitochondria in pain, on the other hand, is less investigated (Flatters, 2015). However, the 
connection of mitochondrial abnormality to painful peripheral neuropathies caused by 
chemotherapy, diabetes, and trauma-induced nerve damage in rodents and humans was shown by 
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several studies (Fidanboylu et al., 2011; Flatters, 2015; Lim et al., 2015; Zhao et al., 2015). 
Mitochondrial dysfunction appears to arise from several factors such as alterations in the ETC activity 
(Baloh, 2008; Fernyhough, 2010; Joseph et al., 2009; Osio et al., 2006), a simultaneous enhancement 
of reactive oxygen species (ROS) causing oxidative stress (Kim et al., 2004; Figure 4) or mitochondrial 
calcium handling (Shishkin et al., 2002). Rouwette and colleagues also demonstrated an association 
between sensory neuron mitochondrial dysfunction and chronic inflammatory pain. They performed 
an unbiased proteome profiling of DRG from CFA-injected mice that revealed a myriad of 
differentially expressed proteins implicated in mitochondrial functioning, including ETC subunits 
mainly of complex I. Inhibition of the latter in vivo by Rotenone, reduced CFA-induced hyperalgesia 
(Rouwette et al., 2016). Furthermore, inflammatory and neuropathic pain conditions are linked to 
increased superoxide production in the spinal cord and elevated mitochondrial oxygen consumption 
in the sciatic nerve, respectively (Lim et al., 2015; Schwartz et al., 2009). In addition, a recent study 
identified the methyltransferase FAM173B that hyperpolarized mitochondria upon overexpression 
and thereby promoted mitochondrial and neuronal (cytosolic) ROS generation after peripheral 
inflammation that caused microglia activation and persistence of inflammatory pain (Willemen et al., 
2018; partly in Figure 4). 
  




Figure 4: Dysfunctional Mitochondria & Chronic Pain  
Proposed model for the connection between dysfunctional mitochondria and persistent inflammatory pain. 
Inflammation might negatively affect mitochondria, causing malfunctioning organelles by alterations in 
activity/expression of ETC complexes. These changes can lead to enhanced ROS production resulting in 
oxidative stress, which stimulates microglia/macrophages and thereby supports persistent inflammatory pain. 
The illustration was created by modifying images purchased in the PPT Drawing Toolkits-BIOLOGY Bundle from 
Motifolio, Inc. These Toolkits were kindly provided by the group of translational pain research, PI Prof. Esther 
Pogatzki-Zahn. Figure generated after (Willemen et al., 2018). 
1.4 Inadequate Pain Medication 
Side effects limit the currently available treatments for pain. In general, the basis for analgesia is 
either an increase in inhibition or decrease in excitation of the nervous system. One example are 
opioids that decrease neurotransmitter release in the presynapse and hyperpolarize neurons in the 
spinal cord, brainstem and cortex postsynapse (Finnegan et al., 2005). Potassium-channel opening 
and sodium-channel blocking anticonvulsants diminish excitation of the nervous system. Inhibitors of 
amine uptake, on the other hand, potentiate inhibitory transmitter actions in the spinal cord and 
brain (Micó et al., 2006; Wood, 2006). The problem about centrally-acting drugs (e.g. 
antidepressants, anticonvulsant, opioids, sodium-channel blockers targeting widely expressed 
channels/ receptors) is a high risk of side effects that can manifest as loss of cognitive function, 
sedation, somnolence or dizziness (Patapoutian et al., 2009). Opioids can also produce respiratory 
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depression, addiction, tolerance and hyperalgesia after chronic application (Ji et al., 2014).  
Moreover, the most common strategy to treat inflammatory pain includes the inhibition of the 
accumulation/ synthesis of inflammatory soup components. This is best illustrated by nonsteroidal 
anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, Aspirin) that decrease inflammatory pain and 
hyperalgesia by cyclooxygenase (COX1 and COX2) inhibition, which is involved in prostaglandin 
synthesis (Basbaum et al., 2009). Unfortunately, selective COX2 inhibitors are limited by 
cardiovascular defects upon long-term application (Ji et al., 2011). Besides, the high number of 
inflammatory mediators acting in parallel makes interruption of their effects a fairly inadequate 
treatment for inflammatory pain (Woolf and Ma, 2007). A number of other strategies targeting 
specific sensitizers are under development. The main approach includes the blocking of NGF or TNFα 
action with neutralizing antibodies. Anti-TNFα therapies have been quite effective in the treatment 
of patients with inflammatory disease (e.g. rheumatoid arthritis) (Atzeni et al., 2005). However, its 
mode of action is still unclear (Noack and Miossec, 2017), which would be an useful information for 
the design of optimized therapies and predicting patient responses (Cook et al., 2018). It is also 
possible that TNFα-targeted approaches cause infection by immunosuppression in the longer term (Ji 
et al., 2011). Anti-NGF as anti-TNFα antibodies will likely always have a ceiling effect. Given the 
presence of other sensitizers, they might only reduce but not eliminate pain (Woolf and Ma, 2007).  
An alternative approach to develop novel analgesics is to target the DRG that harbor primary sensory 
neurons expressing receptors and ion channels that are crucially implicated in the beginning of the 
pain pathway (Basbaum et al., 2009; Patapoutian et al., 2009; Richards and McMahon, 2013). The 
largest group of nociceptive ion channels is the TRP channel family (Clapham, 2003; Dhaka et al., 
2006; Julius and Basbaum, 2001), which is mainly expressed in these neurons. Therefore, specifically 
targeting them might reduce side effects of pain medication (Patapoutian et al., 2009). However, this 
approach has also encountered constrictions by on-target side effects. Especially, early TRPV1 
antagonists caused pronounced hyperthermia in animal models (Garami et al., 2010; Gavva et al., 
2007; Honore et al., 2009; Wong and Gavva, 2008) and in clinical trials (Khairatkar-joshi and Szallasi, 
2008). (Bourinet et al., 2014). 
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1.5 Aim of the Study 
An entire understanding of the mechanisms responsible for chronic pain is still missing, even though 
great progress has been made by identifying ion channels, receptors and signaling proteins that are 
implicated in nociception and pain (Bennett and Woods, 2014; Patapoutian et al., 2009; Raouf et al., 
2010). Hence, the development of therapeutic interventions that target proteins specifically 
implicated in chronic pain, while leaving an individual’s ability to detect noxious stimuli intact, is in 
urgent need (Bourinet et al., 2014). The basis for this approach would be the identification of these 
proteins wherein a big step forward was taken by Rouwette and colleagues. They were able to 
quantify changes in the DRG proteome in two mouse models of chronic pain and could identify 
alterations in dozens of proteins that have not been identified in the pain context before. The 
implication in nociceptive signaling and pain of selected candidates was shown by functional 
validation that elucidated the biological relevance of the proteomics data (Rouwette et al., 2016). A 
further approach for improvement of pain medication would be a better translation from animal 
models to patients (Gregory et al., 2013). Chronic pain models are often critized, because they do not 
fully illustrate pain entities such as spontaneous pain that is clinically relevant (Cobos et al., 2012; 
Mogil et al., 2010; Urban et al., 2011). 
 
This study was therefore aimed at functionally investigating the uncharacterized mitochondrial 
protein TM which was identified and shown to be downregulated in the proteomics study of 
Rouwette and colleagues (Rouwette et al., 2016). Its in vitro and extensive in vivo characterization by 
a broad range of behavirol paradigms including tests for spontaneous and stimulus evoked pain will 
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Table 1: Lists of Reagents and Kits  
Product Company 
(NH4)HCO3 (Ammonium bicarbonate buffer) Roth 
10X HBSS (Hank’s balanced salt solution) Life Technologies 
10X PBS (Phosphate-buffered saline) pH 7.4 
 
Life Technologies 
5 x MyTaq Reaction Buffer Bioline 
6-Aminohexanoic acid Sigma-Aldrich 
ADP (Adenosine diphosphate) Roche 
ATP (Adenosine tiphosphate) Roche 
Agarose Roth 
Ampicillin Roth 
Antimycin A Sigma-Aldrich 
AraC (Cytosine arabinoside)  Sigma-Aldrich 
 





BPE (Bovine pituitary extract)  Life Technologies 
 
BSA (Bovine serum albumin) Sigma-Aldrich (Cell culture) 
Roth (Mitochondria Assays) 
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CFA (Complete Freund’s Adjuvant) Sigma-Aldrich 
Collagen 1, rat tail Life Technologies 
Collagenase Worthington 
 
Complete protease inhibitor Roche  
Complex IV rodent enzyme activity dipstick assay kit 
 
Abcam 
Coomassie brilliant blue Serva 
CsCl (Cesium chloride) Sigma-Aldrich 
 
D-PBS (no calcium, no magnesium) Life Technologies 
 
DDSA (Dodecenylsuccinic acid anhydride) Serva 
 
DH5α E. coli competent cells Life Technologies 
DHE (Dihydroethidium) Invitrogen 
 
DMEM (Dulbecco’s modified eagle medium), GlutaMAX Life Technologies 
 
DMEM (Dulbecco’s modified eagle medium)/F-12, GlutaMAX Life Technologies 
DMP Tris(dimethylaminomethyl)phenol Serva 
DMSO (dimethyl sulfoxide) Sigma-Aldrich 
 
dNTPs (Deoxyribose nucleoside triphosphate) Bioline (Genotyping), Thermo 
Scientific (Cloning) 
Donkey serum Dianova 
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DTT (dithiothreitol) Callbiochem 
EcoMount Biocare Medical 
EGTA (Ethylene glycol tetraacetic acid) Roth 
Emetine Sigma-Aldrich 
Fast digest enzymes: BamHI, Eco105I, EcoRV, Kpnl 
 
Thermo Scientific 
Fast digest green buffer Thermo Scientific 
FastAP thermosensitive alkaline phosphatase Thermo Scientific 
FBS (Fetal bovine serum) Life Technologies 
 




















Growth factors (NGF, GDNF, BDNF, NT-3, NT-4) 
 
R&D Systems 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Life Technologies (Imaging) 
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 Roth (Mitochondria Assays) 
Horse serum Life Technologies 
 
HRM Calibration Kit Biognosys 
Human chorionic gonadotropin Ovogest 
Hygromycin B Life Technologies 
Iodoacetamide Sigma-Aldrich 
KCl (Potassium chloride) Roth 
KCN (Potassium cyanide) Fluka 
KH2PO4 (Potassium dihydrogen phosphate) Roth 
L-glutamine Biozym 
Laminin Life Technologies 
LB (Lysogeny broth) agar Roth 
Ligase buffer Life Technologies 
Lipofectamin RNAiMAX Invitrogen 
Liquid chromatography (LC) solvent Sigma-Aldrich 
Mannitol Roth 
MEM-EARLES&L-GLUT Life Technologies 
Methylene blue Merck 
MgCl2  (Magnesium chloride) Roth (PCR, Electrophysiology) 
Merck (Mitochondria Assays) 
MgSO4 (Magnesium sulfate) Invitrogen 
MitoSOX™ (Red mitochondrial superoxide indicator) Life Technologies 
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MNA (Methylnadic anhydride) Serva 
 
Mouse NGF 2.5S TMH Medizinhandel OHG 
 
Mustard oil (Allyl isothiocyanate, AITC, MO) Sigma-Aldrich 
 
MyTaq HS DNA polymerase 
 
Bioline 
Na2CO3 (Disodium carbonate) Roth 
Na2HPO4 (Disodium hydrogen phosphate) Merck 
NaCl (Sodium chloride) 
 
Merck 
NaH2PO4 (Sodium dihydrogen phosphate) 
 
Merck 
NucleoSpin gel Machery-Nagel 
NucleoSpin RNA extraction kit 
 
Machery Nagel 












PCR Clean-up kit Machery-Nagel 
Penicillin/Streptomycin Life Technologies 
 
PFA (paraformaldehyde), 16% 
 
Electron Microscopy Sciences 
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PFA (paraformaldehyde), powder 
 
Serva 
PFX Reaction buffer Life Technologies 
Platinum PFX DNA polymerase Life Technologies 
Pluronic F-127 20% solution 
 
Life Technologies 
PDL (Poly-D-lysine) Millipore 
PLL (Poly-L-lysine) Sigma-Aldrich 
Power SYBR green PCR master mix Life Technologies 
 
Pregnant mare serum gonadotropin Pregmagon 
Propylene oxide Serva 
 
Pure Link HiPure plasmid filter maxiprep kit  Invitrogen 
Qiazol lysis reagent Qiagen 




RNAscope 2.5 HD assay-red 
 
Advanced Cell Diagnostics 
(ACD) 




RPMI (Roswell park memorial institute) medium Life Technologies 
Slowfade gold antifade reagent with/without DAPI 
 
Life Technologies 
SOC medium Invitrogen 
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Succinate Sigma-Aldrich 
Sucrose Merck (Embedding) 
Roth (Mitochondrial Assays) 
T4 DNA ligase Life Technologies 





TMRM (Tetramethylrhodamine, methyl ester) Invitrogen 
Trifluoroacetic acid Roth 




Tryple express w/ phenol red 
 
Life Technologies 
Trypsin/EDTA (10x) Biozym 
 
Tumor Necrosis Factor alpha (TNF α) 
 
Peprotech 
Uranyl acetate SPI-Chem 
 
Urea Sigma-Aldrich 
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2.2 Mouse Models 
2.2.1 Animal Care and Conditions              
All mice examined in this study were group-housed in individually ventilated cages (IVC) and kept in a 
12 h light/dark cycle (light from 5:00 a.m. to 5:00 p.m.) with water and food ad libitum in the animal 
facility of the Max Planck Institute of Experimental Medicine (MPI EM) or University Medical Center 
Münster (UKM) (collaboration with the Group of Translational Pain Research, PI Prof. Esther 
Pogatzki-Zahn). Experiments were performed during the light phase and according to MPI EM 
guidelines and with permission of the Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit (LAVES) or Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-
Westfalen (LANUV). TM wild type (WT) vs. knock out (KO) littermates were assessed in a genotype-
blinded-fashion with an age between 8-14 weeks (w). Both genders were analyzed and included in 
experiments distributed by age and genotypes to respective cohorts.  
 
2.2.2 Generation of Knock Out (KO) Mice 
TM KO lines were generated by CRISPR/Cas9 technology (Mali et al., 2013) in collaboration with the 
DNA core and transgenic facilities of the MPI EM. C57Bl/6JRj females (3-4 w) were superovulated 
(pregnant mare serum gonadotropin (7.5 U) and human chorionic gonadotropin (5 U)) and mated 
with C57Bl/6JRj males. Fertilized eggs were collected on the day of plug after the females were 
sacrificed due to cervical dislocation (adapted from Brooke et al., 2007). Microinjection of CRISPR 
reagents (hCAS9_sgRNA_HDR.DNA (1 gRNA/loxP site) = 5 + 5_6.2 + 6.2_20 ng/µl) into the pronucleus 
and the cytoplasm of zygotes at the pronuclear stage followed by usage of the Eppendorf Femtojet 
and Femtotip II capillaries. The procedure was performed with a constant flow under visual control 
on an inverted microscope (40x air objective and DIC optics). Subsequently, pseudopregnant NMRI 
fosters received injected zygotes bilaterally in their oviduct. In this way floxed TM (Exon 1) mice were 
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Tmem160 floxed allele  
-Equal to WT Sequence but loxP sequences inserted 
-Primer = blue (initial genotyping to confirm correct HDR fragment composition and insertion) 
 34811 + 34820 upstream Exon 1 loxP1_HDR; 34481 + 34930 Exon 1 loxP2_HDR; 34811 + 35087 HDR 
fragment 
-Primer = light blue (genotyping after in vivo CRISPR reagent microinjection) 
35690 + 35691 WT (235 bp); 35690 + 35691 floxed allele (269 bp); 34929 + 35691 Exon 1 deletion 
(202 bp) 
-EcoRV and KpnI = red (cKO 3251 bp EcoRV to KpnI) 
-HDR fragment = underlined (3251 bp) 
-PAM sites = bold 
-guideRNA target site = green 
-loxP sequences = orange 
-Exon1, Exon2, Exon3 = pink 
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2.2.2.1 cTMEM160_cKO r/r x Ella Cre 
 
The constitutive TM KO was generated by crossing the Ella Cre (adenovirus Ella promoter, 
recombination E0.5 from Jackson Laboratory) driver line (Lakso et al., 1996) with floxed TM mice. 
2.2.2.2 cTMEM160_cKO r/r x Dhh Cre 
 
The Schwann cell specific TM KO mice were generated by crossing floxed TM mice with the DHH-Cre 
driver line (Jackson Laboratory). Desert hedgehog (DHH) is a differentiation marker of Schwann cell 
precursors (SCPs) resulting in recombination between E11-E13.5 (Jaegle et al., 2003). 
2.2.2.3 cTMEM160_cKO r/r x Advillin Cre 
 
The use of Advillin Cre driver mouse lines resulted in TM deletion in sensory neurons of dorsal root 
ganglia (DRG) and trigeminal ganglia (TG) starting between E14.5 and E16.5 (Zurborg et al., 2011). 
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2.2.3 Validation of KO Mice 
2.2.3.1 Genotyping 
 
The AGCT lab of the MPI EM examined genotypes according to standard PCR methods using DNA 
isolated from tail biopsies and self-synthesized primers (Table 4: List of Primers). 
 
Table 2: PCR Master Mix Genotyping  
Amount (µl) Reagent 
9.8 H2O 
 
4.0 5 x MyTaq Reaction Buffer with 5 mM dNTPs, 15 mM MgCl2 
1.0 50 mM MgCl2  
0.2 MyTaq_HS DNA Polymerase, 5 units/μl  




20.0 total  
 
 
Final concentration: Mg: 5.5 mM, dNTPs: 1 mM, DNA Pol.: 0.05 U/µl, Primer set: 0.2 pmol/µl-, 
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Table 3: PCR Cycle Genotyping  























2.2.3.2 Real Time Quantitative PCR (qRT-PCR) 
 
RNA of snap-frozen DRG tissue was purified with the NucleoSpin RNA XS Kit as specified by the 
manufacturer. Obtained RNA was further processed to cDNA with the QuantiTect reverse 
transcription kit. First of all, genomic DNA (gDNA) contamination was removed by incubation in a 
thermal cycler (Bio-Rad T100) for 6 minutes at 42°C after addition of gDNA wipe out buffer. 
Afterwards, cDNA was synthesized by adding a master mix composed of reverse transcriptase (RT), 
5x RT buffer and primer mix to the gDNA wipe out product, followed by incubation at 42°C for 
30 minutes and at 95°C for 3 minutes. Subsequently, gene expression levels (Table 4: List of Primers) 
were quantified in a LightCycler 480 (Roche) with the SYBR green system (Power SYBR green PCR 
master mix). cDNA (ca. 1-100 ng) or H2O (neg. control) was pipetted in triplicates and the master mix 
(H2O, respective primers, SYBR green) was added. qPCR specificity was validated by analyzing the 
melting curve of the amplified product. The Cp (crossing point-PCR-cycle) values, meaning the cycle 
number where SYBR green fluorescence is higher than the background, were normalized to the 
commonly used housekeeping genes (β-Actin and GAPDH). Ultimately, relative expression changes 
were identified using the “fit point” and “2nd derivative maximum” analysis of the LightCycler 480 
(according to Avenali et al., 2014).  
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Snap-frozen sciatic nerves (SN) were processed equally with the exception of RNA purification. Other 
than DRG, SN RNA was isolated with the RNeasy mini kit. First, SN were homogenized in Qiazol lysis 
reagent using the Precellyse24 (Bertin Technologies, 2x shaking for 10 s at 5500 rpm). Afterwards, 
RNA was extracted according to specifications for “RNA Isolation from fatty tissues” (protocol 
adapted from manufacturer’s instructions by the Department of Neurogenetics, PI Prof. Klaus-Armin 
Nave, Ph.D). 
 
Table 4: List of Primers  
Primers Sequence (5’->3’) Used for 
TMEM160 FW upstream Exon 1: CCTATGTGTGAAGAACATTGAATCT            
REV upstream Exon 1: ACTACAAATCCCAGAGATCAATG               
REV downstream Exon 1: CTTCTTCCTAACCGTAGCCTCCT             
FW Exon 1: TCACCAATGGTTGTGTCGCTCC                                       








TMEM160 FW upstream Exon 1: ACTAGTACAAGTTTTGTTTCCTGGC              
FW downstream Exon 1: GGCCAGAGTAAGGCAAGCATC               
REV downstream Exon 1: CGGTCTCTCACCTAGGCAGT 
Genotyping 




















Iba1 FW: GGATTTGCAGGGAGGAAAA 
REV: TGGGATCATCGAGGAATTG 
qRT-PCR 
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β-Actin FW: GATCAAGATCATTGCTCCTCCTG 
REV: CAGCTCAGTAACAGTCCGCC 
qRT-PCR 
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2.2.3.3 In situ Hybridization (ISH) 
 
In situ hybridization (ISH) was performed with the RNAscope 2.5 HD Detection Kit (Red) for FFPE 
(Formalin-Fixed Paraffin-Embedded) sections. The first step was deparaffinization of sections 
(described in detail in section 2.6.3). Afterwards, 5-8 drops of hydrogen peroxide were added to each 
section for 10 minutes at room temperature to block endogenous peroxidase activity, followed by 
washing (2x 3-5 times washing in ddH2O). Subsequently, slides were boiled for 5 minutes in 1x target 
retrieval solution in order to improve RNA accessibility for RNA scope probes due to breaking of cross 
links (which have occurred from tissue fixation). After washing in ddH2O and 100% EtOH, sections 
were air dried and circled with the Immedge hydrophobic barrier pen. 5 drops of Protease plus were 
added and slides were incubated for 30 minutes in a humidified chamber in the HybEZ oven (at 40°C, 
ACD). This step was performed in order to enhance RNA accessibility. After washing in ddH2O, 4 
drops of RNA scope probe (for the RNA of interest) were added and incubated for 2 hours at 40°C in 
the HybEZ oven. After slides were washed 2x in 1x wash buffer several amplification steps followed 
(Amp1: 30 minutes at 40°C; Amp2: 15 minutes at 40°C; Amp3: 30 minutes at 40°C; Amp4: 15 minutes 
at 40°C; Amp5: 30 minutes at 40°C; Amp6: 15 minutes at room temperature). After each 
amplification process slides were washed 2x in 1x Wash buffer. Finally, the signal was detected by 
applying freshly mixed RED-B and RED-A (1:60, 10 minutes incubation at room temperature). When 
slides were washed in ddH2O a nuclei counterstaining with Mayer’s Hemalaun (1:1 with ddH2O for 2 
minutes) was performed and slides were washed again (tap water and ddH2O). Before slides were 
mounted with EcoMount, they had to be dried at 60°C in a dry oven for 15 minutes and dipped into 
fresh pure xylene. Finally, the sections were air dried for 5 minutes and imaged with the 10x air 
objective under the Zeiss Axio Observer Z1 inverted microscope (bright field mode), according to 
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2.3 Murine Pain Models 
2.3.1 Inflammatory Pain Model: CFA 
Inflammatory pain was induced by the unilateral injection of CFA (Complete Freund’s Adjuvant, 10 µl 
of 1 mg/ml) into the plantar hind paw. The adjuvant was constituted of heat-inactivated 
mycobacteria (Mycobacterium tuberculosis) and evoked an inflammation with a peak after 24 hours 
and persisted for around 7 days. PBS was used as vehicle and injected in a uniform manner. The mice 
were assessed by the performance of behavioral paradigms pre and 1, 2, 3, 5 and 6 days post 
injection (Minett et al., 2011; Petrus et al., 2007).  
 
2.3.2 Neuropathic Pain Model: SNI 
Neuropathic pain was evoked by performing a spared nerve injury (SNI) in one of the hind legs of 8-
10 weeks old mice. This form of injury was induced by a 1 mm excision of two sciatic nerve branches. 
Namely, the common peroneal and tibial nerve, while the sural nerve was left untouched. 10 
minutes before the operation mice were injected i.p. (intraperitoneal) with buprenorphine (analgesic 
agent, opioid; 0.07 mg/kg body weight) followed by a subsequent anesthesia with 1.5-2.5 % 
isoflurane O2/Air mix. The procedure usually took 20 minutes and was performed on a heating pad to 
maintain body temperature. Further pain management was performed 5-6 hours later by i.p. 
injection of carprofen (5 mg/kg, nonsteroidal anti-inflammatory drug (NSAID)) and 1-3 days post 
surgery. In order to make the sciatic nerve accessible, the hind leg was shaved, disinfected and a 
small incision into the skin was performed to expose the biceps femoris. The muscle was cut to 
expose the sciatic nerve with its branches (common peroneal, tibial and sural nerve). Afterwards, the 
common peroneal and tibial nerves were ligated with a suture, while the sural nerve was left 
untouched. After the axotomy the muscle parts were moved back together followed by wound 
closing with sterile staples. Sham operated mice were used as controls. The surgery was performed 
in a similar manner without nerve transection. The mice were behaviorally examined before surgery, 
at post operation day (POD) 7, 14, 21, and 28 and were subsequently sacrificed for organ collection 
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2.4 Phenotyping of Mice  
2.4.1 Assessment of Motor Performance                     
Motor performance of mice was investigated with the TSE RotaRod System Advanced (TSE Systems). 
It is equipped with a rotating central axis (diameter: 3 cm, width: 6 cm) and 5 lanes for a 
simultaneous measurement of 5 mice. The animals were adapted to the device for 2 consecutive 
days. On day 3, a potential motor impairment was investigated by using the accelerated rotation 
mode (5-52 rpm within 5 minutes). Time spent on the central axis was measured for individual 
animals until falls were detected by a light-beam causing the timer to stop. Mice had to perform 5 
times with a recovery phase of 10 minutes (according to Gess et al., 2011). 
 
2.4.2 Evoked Pain Paradigms 
2.4.2.1 Mechanical Hypersensitivity: Plantar Aesthesiometer           
In order to investigate mechanical hypersensitivity in mice after the induction of pain, the animals 
were placed in plastic boxes on a grid. Before testing started, they were acclimated for 2 hours until 
exploratory behavior ended. Subsequently, the Plantar Aesthesiometer (Ugo Basile) equipped with a 
filament was placed beneath the mice. The filament was brought in contact with the hind paws until 
they were retracted. More precisely, the filament is slightly pricked into the paws by an increasing 
force of 0-10 g within 40 seconds. Withdrawal latency and respective force values were collected 5 
times per paw (according to Avenali et al., 2014; Minett et al., 2011). 
2.4.2.2 Mechanical Hypersensitivity: Von Frey Filaments  
 
Mice were acclimated for 30 minutes on an elevated grid followed by examination of withdrawal 
threshold to mechanical stimuli given by calibrated von Frey-filaments (14, 20, 39, 59, 78, 98, 147, 
255 mN bending force). Stimuli were given to the plantar surface of each of the hind paws starting 
with the lowest bending force until a response occurred or cut-off was reached (255 mN). The 
median from 3 measurements per paw was considered as withdrawal threshold. Force of the next 
filament was applied (522 mN) if no response was evoked by using the other filaments. This method 
was performed in collaboration with the Group of translational pain research, PI Esther Pogatzki-
Zahn (according to Reichl et al., 2016). 
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2.4.2.3 Thermal Hypersensitivity: Hargreaves Apparatus 
 
Thermal hypersensitivity of mice was identified with the Hargreaves Apparatus (Ugo Basile) or the 
IITC Life Science Plantar Test Analgesia Meter (Life Science). Before testing started, mice were 
acclimated for 2 hours in plexiglas boxes positioned on a glass plate. Infrared heat (set to 20: 
Hargreaves Apparatus) or in case of IITC the radiant heat (set to 15 % light intensity) beam was 
positioned beneath the hind paw surfaces. 5 withdrawal latency values were collected per respective 
hind paw (according to Avenali et al., 2014; Minett et al., 2011). 
2.4.2.4 Movement-Evoked Pain Behavior: Catwalk                         
 
The Catwalk system (Noldus) was used for automatic gait analysis in order to assess movement-
evoked pain behavior. Mice were passing through a corridor upon an illuminated (green LED) glass 
plate to visualize footprints, while a video camera was detecting them from below. To enhance the 
contrast, red light was shining down from the lid. Afterwards, the resulting video sequences were 
analyzed with a specialized software (Catwalk XT, Noldus). Parameters like stand and print area as 
well as swing speed and duty cycle were analyzed. The test was performed 3 times per mouse 
(Caballero-Garrido et al., 2017). 
 
2.4.3 Non-Evoked Pain Paradigms 
2.4.3.1 Non-Evoked Pain (NEP) Behavior 
 
Spontaneous pain was assessed with a behavioral test called non-evoked pain behavior (NEP). In 
order to measure foot print intensities, mice were placed in boxes positioned on green illuminated 
plexiglas covered with red illuminated Plexiglas to increase the contrast. Acclimatization of animals 
was performed for a duration of 30 minutes until exploratory behavior ended. Afterwards, 20 
pictures were taken within a time frame of 10 minutes (every 30 seconds 1 picture). Subsequently, 
the foot print intensities were analyzed with Image J (foot print intensity macro from the Group of 
Translational Pain Research, PI Esther Pogatzki-Zahn) by assessing the pixel number. Finally, the ratio 
between non-operated and operated paw was calculated. The method is a combination of the 
illuminated footprints (used in the Catwalk system (described in 2.4.2.4)) and observations from the 
non-evoked pain assessment (using a cumulative pain score, Reichl et al., 2016). The method was 
established and performed by the Group of Translational Pain Research, PI Esther Pogatzki-Zahn 
(Linnemann et al., 2018, Poster World Congress on Pain 2018, Boston). 
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2.4.4 Acute Pain Behavior            
Acute pain behavior was explored by injection of the TRPV1 (transient receptor potential vanilloid 1) 
agonist Capsaicin (0.5 µg/10 µl) or Vehicle (5 % EtOH/D-PBS) into the left hind paw. The time mice 
spent licking, flicking and lifting of the paw were investigated over a time period of 10 minutes. 
Afterwards, mechanical sensitivity was assessed with the Plantar Aesthesiometer (Ugo Basile) for 1.5 
hours (Caterina et al., 2000).  
2.5 Cell Culture 
2.5.1 DRG Culture and Nucleofection              
Coverslips (12 mm) or MatTek dishes were coated with poly-D-lysine (PDL, 1 mg/ml) for 1.5 hours at 
37°C followed by 3x washing in D-PBS and coating with laminin (20 µg/ml) for 0.5 hours at 37°C. 
Subsequently, 8-12 w old C57Bl/6JRj or TM KO mice and their respective controls were sacrificed by 
CO2 according to the animal welfare law. Mice were decapitated and the hairy back skin was 
removed. Afterwards, the backbone was excised and the covering superficial muscle tissue was cut 
open. The vertebrae were longitudinally bisected revealing the spinal cord and DRG positioned in the 
intervertebral foramina. Dorsal and ventral roots were removed and ganglia were collected in 1 ml 
serum free medium (DMEM/F-12+Glutamax). DRG and medium were transferred to 1 ml Collagenase 
(12 mg/ml) and digested for 1 hour at 37°C (mixed every 15 minutes). Trituration with P1000 tip and 
further digestion in Papain (final dilution 1:10) followed for 0.5 hours at 37°C. Afterwards, cells were 
centrifuged (1000 rpm for 1 minute), 1 ml of serum free medium was added, cells were again 
triturated and an additional ml of serum free medium was pipetted on top. Bovine serum albumin 
(BSA, 0.15 g/ml) was slowly given underneath the cells suspension and the column was centrifuged 
for 10 minutes at 1000 rpm. A cell pellet was formed on the bottom of the falcon covered by the BSA 
layer, a cell debris layer and on top the medium layer. All layers were removed with a Pasteur pipette 
in the following order: cell debris layer, medium, BSA. Cells were now re-suspended in the proper 
amount of medium with serum (DMEM/F-12+Glutamax+horse serum) plus growth factor (100 ng/ml 
NGF) and were plated on coverslips or dishes. After 20 minutes cells were covered with 1 ml medium 
with serum and NGF. Cells were used after 24 h for calcium or live imaging experiments (according to 
Avenali et al., 2014; Narayanan et al., 2016). 
Nucleofection was performed with the P3 Primary Cell 4D-Nucleofector X Kit in the 4D-Nucleofector 
X Unit (Lonza) after the abovementioned centrifugation for 10 minutes at 1000 rpm. Supernatant 
was removed from cell pellet followed by re-suspension in 36 µl nucleofector solution (P3 primary 
neurons nucleofector solution including supplement). Subsequently, 0.5 µg plasmid (pCMV6-
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TMEM160-Myc-DDK single or in combination with HyPer-mito-YFP or pCDNA3.1-myc-His) were 
added to cell suspension, transferred to a 16-well cuvette and inserted into the nucleofector 
(program DC 104). After electroporation the cuvette was immediately removed and 40 µl of RPMI 
(calcium free) were added followed by a recovery incubation for 10 minutes at 37°C. 60 µl medium 
(DMEM/F-12+Glutamax) were added and 40 µl of cell suspension was plated on 3 coverslips/dishes. 
After a 20-minute incubation at 37°C cells were covered with 1 ml medium supplemented with 
serum and growth factors (DMEM/F-12+Glutamax + 10 % horse serum + 100 ng/ml NGF + 50 ng/ml 
GDNF + 50 ng/ml NT-3, and 50 ng/ml NT-4). In order to reduce toxicity half of the medium was 
replaced by fresh medium after 2 hours. After 3dIV (day in vitro) cells were used for 
immunocytochemistry (according to Avenali et al., 2014, Narayanan et al., 2016). HyPer-mito-YFP 
was kindly provided by the Department of Metabolic and Redox Signaling, PI Prof. Dr. Michael 
Müller. 
2.5.2 Schwann Cell (SC) Culture and Nucleofection           
Rat pups (postnatal day 3) were decapitated and sciatic nerves were dissected and placed in a culture 
dish filled with medium (DMEM+Glutamax+Pen/Strep) on ice. The epineurium was removed and de-
sheathed nerves were collected in a fresh culture dish filled with the same medium. Subsequently, 
nerves were dissociated in 300 µl Trypsin (2.5 mg/ml in PBS) and rat-tail collagenase (approx. 
800 U/ml) in a culture dish for 1 hour at 37°C. Afterwards, nerves were triturated by P1000 and P200 
tips (each 10x) and digestion was stopped by adding 4 ml medium with serum 
(DMEM+Glutamax+Pen/Strep + 10 % fetal bovine serum (FBS)). Cell suspension was centrifuged at 
1000 rpm for 10 minutes and the supernatant removed. After re-suspension in 1 ml medium with 
serum the cells were plated on poly-L-lysine (PLL, 100 µg/ml, 1 h at 37°C) coated dishes. After 24 
hours 10 µl AraC (cytosine arabinoside) were added to 2 ml cell suspension (final conc. 10-5 M) and 
cultured for 3 days in order to eliminate fibroblasts. AraC containing medium was replaced by fresh 
expansion medium (DMEM+Glutamax+Pen/Strep + 10 % FBS +70 µg/ml BPE (Bovine pituitary 
extract) + 4 µM Forskolin). This medium allowed for cell division resulting in confluency after 2-3 days 
when cells were split 1:3 (adapted from Stevens et al., 1998 by Dr. Susanne Quintes, Department of 
Neurogenetics, PI Prof. Klaus-Armin Nave, Ph.D). 
 
Nucleofection was performed in the same fashion as abovementioned for the DRG culture with slight 
modifications: Cells were washed in D-PBS (1x) and detached with 1x trypsin followed by a 
centrifugation at 1000 rpm for 10 minutes. The supernatant was discarded and cells were re-
suspended in 1 ml medium ((DMEM+Glutamax+Pen/Strep + 10 % FBS) and amount was quantified by 
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using the Neubauer counting chamber. Dilution of cells in respective quantity of medium (200.000 
cells/electroporation) followed. Afterwards, SC were centrifuged again (1000 rpm, 10 minutes), 
supernatant was removed and cells were re-suspended in nucleofector solution. Procedure was 
performed exactly as for DRG culture with a difference in the program used: CA 138 and usage of SC 
medium (modified from Avenali et al., 2014, Narayanan et al., 2016).  
 
2.5.3 SC DRG Co-Culture  
Pregnant mice were sacrificed by CO2, followed by the opening of the abdomen. The uterus was 
excised and transferred to a culture dish on ice filled with basal medium (MEM-EARLES&L-GLUT). 
Mouse embryos (E13.5) were released and placed (one at a time) into a fresh dish with medium in 
order to remove extremities (paws were used for genotyping) and organs. Subsequently, the spinal 
cord was exposed by cutting the rips and removing the surrounding tissue. The spinal cord with its 
DRG attached was transferred into a new medium-dish where all DRG were plugged off. The medium 
containing DRG from all embryos was pipetted into a falcon tube and centrifuged (800 rpm, 5 
minutes). The medium was removed and replaced by 1.5 ml Trypsin (0.25 %) followed by the 
digestion for 1 hour at 37°C (water bath). The addition of 4 ml medium with serum stopped the 
digestion (MEM-EARLES&L-GLUT+Pen/Strep (100 U/ml) + 10 % FBS). Cells were re-suspended with a 
5 ml glass pipette and P1000 tip. 10 µl of cell suspension were saved for counting and the remaining 
solution was centrifuged (800 rpm, 8 minutes). After supernatant removal cells were re-suspended in 
the proper amount of medium (MEM-EARLES&L-GLUT + Pen/Strep + 10 % FBS + 50 ng/ml NGF; 
150000 cells/CS) and distributed to CS (40 µl/CS). CS (18 mm) were coated in advance with collagen 
and arranged in 12 well plates. The cells were allowed to settle down over night and wells were filled 
up with 1 ml medium the next morning. After letting them grow for 1 week, basal medium was 
replaced by myelination medium (MEM-EARLES&L-GLUT + Pen/Strep + 10 % FBS + 50 ng/ml NGF + 
50 µg/ml ascorbic acid), which had to be changed every second day. Myelination could be seen 7 
days post induction. In order to assess potential differences in myelination CS were stained for MBP 
(myelin) and Tuj (axons) (after ICC protocol: section 2.7.1, Table 5: Primary Antibodies). Images were 
taken with the Zeiss Axio Observer Z1 inverted microscope (20x air objective) in a random fashion (12 
images/CS; 3 CS/genotype; 2 separate experiments) and MBP segments were counted (protocol 
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2.5.4 HEK293T Cell Culture and Transfection 
Coverslips were coated in the same way with PDL and laminin as aforementioned for DRG culture 
(section 2.5.1). HEK cells were maintained in medium composed of DMEM+Glutamax + 10 % FBS + 
1 % penicillin/streptomycin at 37°C and 5 % CO2 in T-75 flasks. Medium was aspirated and HEK cells 
were washed in 10 ml warm D-PBS. After D-PBS removal cells were detached with 1 ml TrypLE 
Express. 9 ml of warm medium was added and 1 ml of this cell suspension was added to a new flask 
comprising 9 ml of warm medium. The same dilution was performed in an additional flask and 1 ml 
of the cells suspension was distributed on coverslips arranged in a well plate. Subsequently, the 
transfection mixture (100 µl OPTIMEM medium, 3 µl FuGENE and 0.5 µg plasmid (pCMV6-TMEM160-
Myc-DDK or pCDNA3.1-myc-His)) was distributed equally on the respective coverslips after an 
incubation of 20 minutes. Immunocytochemistry (after ICC protocol: section 2.7.1, Table 5: Primary 
Antibodies) was performed after 3dIV (according to Avenali et al., 2014, Narayanan et al., 2016). 
2.6 Histology 
2.6.1 Cryo-Embedding             
DRG, SN and spinal cords were collected and stored in 4 % PFA (Paraformaldehyde) over night. 
Subsequently, to protect the tissue from the formation of ice crystals it was placed in 30 % sucrose. 
Cryo-protection was performed overnight followed by tissue embedding in plastic molds filled with 
OCT (Optimal cutting temperature) compound. Tissue blocks were stored at -80°C until cut with a 
microtome cryostat (Leica) (DRG and SN were cut at a width of 10 µm, whereas spinal cords were cut 
at 20 µm, step serial 5 sections à 6 slides) (as described by Avenali et al., 2014). 
2.6.2 Paraffin-Embedding 
Tissue of interest was dissected from mice and fixed in 4 % PFA over night. Afterwards, it was placed 
in 1x PBS and transferred into plastic molds for further processing (1x 50 % EtOH 1 hour, 2x 70 % 
EtOH 2 hours, 2x 96 % EtOH 1 hour, 2x 100 % EtOH 1 hour, 1x 2-Propanol 1 hour, 2x Xylol 2 hours, 2x 
Paraffin wax (60°C) 2 hours). Subsequently, the paraffin-infiltrated tissue was transferred to a 
different plastic mold and adjusted properly for cutting and filled completely with paraffin. When the 
paraffin blocks were cooled down they were cut with a microtome (Leica) in 5 µM thick tissue 
sections (step serial, 5 sections à 6 slides) or stored at room temperature. For proper attachment of 
sections to the slides, they were placed at 37°C over night (according to standard protocols from the 
Department of Neurogenetics, PI Prof. Klaus-Armin Nave, Ph.D). 
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2.6.3 Deparaffinization and Rehydration of Paraffin Sections 
Slides with tissue sections had to be warmed up in a dry oven (60°C for 10-20 minutes) to melt the 
paraffin. Afterwards slides were placed in Xylene at RT (2x 10 minutes), followed by 10 minutes 
incubation in 1:1 Xylene: 2-Propanol (room temperature). Subsequently, sections were rehydrated in 
diverse EtOH concentrations (100 % EtOH, 90 % EtOH, 70 % EtOH, 50 % EtOH, each 5 minutes at 
room temperature) and washed in ddH2O (5 minutes at room temperature). Finally, the slides were 
first placed in citrate buffer (0.01 M, pH 6.0: 450 ml ddH2O+9 ml 0.1 M C6H8O7xH2O+ 41 ml 0.1 M 
C6H5Na3O7x2 H2O) for 5 minutes at room temperature and subsequently boiled in the same buffer 
(10-15 minutes in the microwave), followed by a cool down for 20 minutes leaving the slide in the 
buffer. After this step, sections were incubated in blocking buffer as described in the IHC section 
(2.7.2) (according to standard protocols from the Department of Neurogenetics, PI Prof. Klaus-Armin 
Nave, Ph.D).  
2.7 Fluorescence Staining 
2.7.1 Immunocytochemistry (ICC) 
After 3dIV cells were washed in 1x PBS (3x short, 3x 5 minutes) and subsequently fixed in 4 % PFA for 
10 minutes at room temperature. After washing in 1x PBS, (3x shortly, 3x 5 minutes), the cells were 
covered with blocking solution (5 % donkey serum, 0.4 % TritonX-100 in 1x PBS) for 30 minutes at 
room temperature. Incubation at 4°C over night with respective primary antibodies (diluted in 1 % 
donkey serum, 0.1 % TritonX-100 in 1x PBS (Table 5: Primary Antibodies), followed. Upon 
completion, the cells were washes in 1x PBS (3x short, 3x 5 minutes) and secondary antibody solution 
was added (Table 6: Secondary Antibodies) for 2 hours at room temperature. Finally, coverslips with 
cells were washed again in 1x PBS (3x short, 3x 5 minutes) and mounted with Slowfade gold antifade 
reagent on slides (according to Narayanan et al., 2016). 
 
2.7.2 Immunohistochemistry (IHC) 
Frozen tissue sections were thawed for 5-10 minutes and subsequently surrounded by a fat pen and 
treated for 1 hour with blocking buffer (5 % donkey serum, 0.4 % TritonX-100 in 1x PBS) at room 
temperature to increase the staining specificity. Afterwards, slides were incubated overnight at 4°C 
with primary antibody (diluted in antibody solution, 1 % donkey serum, 0.1 % TritonX-100 in 1x PBS) 
combinations against proteins of interest (Table 5: Primary Antibodies). When the incubation was 
finished the tissue was washed 3x short in 1x PBS in addition to 3x 5 minutes wash in 1x PBS. 2 hours 
incubation with secondary antibodies (Table 6: Secondary Antibodies) followed. Upon completion of 
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incubation time, the tissue was washed again in 1x PBS (3x shortly, 3x 5 minutes) and mounted with 
Slowfade gold antifade reagent with or without DAPI. All incubation steps were performed in a 
humid chamber (according to Avenali et al., 2014). 
 
Table 5: Primary Antibodies  
Target Company Source Dilution 

























































































Table 6: Secondary Antibodies  
Antibody Company Source Dilution 
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2.7.3 Image Acquisition: ICC & IHC 
After mounted slides were dry, images were taken with a Zeiss Axio Observer Z1 inverted 
microscope, with 10x, 20x air or 63x oil objective. The exposure time was kept constant for the same 
staining compared between genotypes or treatment conditions, in addition to secondary antibody 
controls (according to Avenali et al., 2014). 
 
2.7.4 Image Analysis: IHC 
For each condition 7 images were taken and analyzed with Image J. First, brightness and contrast 
were set to get an optimal signal to noise ratio of the staining. To identify a specific staining a 
threshold was set by measuring the mean intensity (AU) of 10 unstained cells + 3x standard 
deviation. A staining was considered positive when its mean intensity was higher than the threshold. 
The mean staining intensity was quantified followed by the threshold subtraction and multiplication 
by the area. Finally this value was divided by the sum of all areas to get the mean 
intensity/pixel/image. These values were taken from all 7 images/condition and last of all the mean 
was determined. In addition, the percentage of cells positive for the protein of interest in regard to 
the total number of cells was determined (cell counter tool from Image J) (according to Avenali et al., 
2014). 
2.8 Live Imaging 
2.8.1 Mitosox Imaging                   
Mitosox is a dye sensitive to mitochondrial reactive oxygen species (ROS), which reveals a red color 
when oxidized. Coverslips with cultured sensory neurons (primary DRG culture) were washed 3 times 
in assay buffer (HEPES, HBSS in H2O) followed by 15 minutes incubation at 37°C in 1 µM Mitosox 
diluted in DMSO and assay buffer. After incubation, cells were washed 3x in assay buffer and the 
coverslip was placed in a chamber and covered with buffer for subsequent imaging with a Zeiss Axio 
Observer Z1 inverted microscope (20 x air objective). 7 pictures were taken in a random fashion and 
mean intensity of the neuronal soma was analyzed with Image J (Plun-Favreau et al., 2012). 
2.8.2 TMRM Imaging  
TMRM (tetramethylrodamine, methyl ester) was used as indicator for mitochondrial dysfunction, 
because of its accumulation capacity in mitochondria with intact membrane potential. Therefore, the 
signal was strong in healthy cells with active mitochondria, whereas a loss of membrane potential 
caused a diminished signal. Primary sensory neurons (DRG culture) were incubated in 3 nM TMRM in 
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assay buffer (HEPES, HBSS in ddH2O) for 1 hour at room temperature. After incubation, cells were 
imaged with the Zeiss Axio Observer Z1 inverted microscope (20x air objective). Images were taken 
every 20 seconds for a time period of 6 minutes (2 minutes baseline (assay buffer + 3 nM TMRM), 2 
minutes 1 µM FCCP (mitochondrial oxidative phosphorylation uncoupler; in assay buffer + 3 nM 
TMRM), 2 minutes wash out (assay buffer). Finally, TMRM mean intensity after membrane potential 
collapse was normalized to baseline and analyzed in axons from 4 squares/image (12 images/CS; 3 
CS/imaging round) (Akude et al., 2011; Nicholls, 2006). 
2.9 Ca2+-Imaging 
Cell intrinsic calcium concentrations were visualized by Fura 2-AM, which is a specific calcium binding 
fluorescent dye. Calcium concentration changes were investigated by measuring the excitation ratio 
of 340/380 nm. 50 µg Fura2-AM were dissolved in 50 µl DMSO and 50 µl Pluronic F-127 and finally 
diluted 1:200 in warm assay buffer (1x HBSS, 10 mM HEPES in ddH2O). After media was aspirated 
from cultured DRG cells they were incubated in Fura2-AM solution for 30 minutes at 37°C. 
Afterwards, cells were washed again 3x in assay buffer and coverslips were transferred to an imaging 
chamber and immediately covered with assay buffer. Subsequently, cells were imaged with the 
MetaFluor Software (Molecular Devices) installed on the Zeiss Axio Observer Z1 inverted microscope 
(20x air objective). Neuronal excitability was assessed by filling the chamber with assay buffer (2 
minutes, baseline), 1 minute 100 nM Capsaicin, 2 minute wash out (assay buffer 2 minutes), 1 minute 
1 µM Capsaicin, 2 minutes wash out (assay buffer), 1 minute 60 mM KCl, wash out (assay buffer, 1 
minute). Experiments were performed 20 hours after plating and cells from both genotypes were 
measured on the same day. Data was analyzed by assessing the percentage of neurons, which 
responded to the respective stimulus. A responder was considered positive when its amplitude peak 
was bigger than the baseline (5 values before given stimulus) plus 20 %. Furthermore, the mean 
amplitude of responders (peak amplitude-mean of baseline) was depicted (according to Avenali et 
al., 2014; Sondermann et al., 2018). 
 
2.9.1 Ca2+-Imaging upon TNFα Stimulation  
DRG culture cells were stimulated with TNFα (100 ng/ml in PBS + 0.1 % BSA, known to promote ROS 
formation (Valko et al., 2007)) or vehicle (PBS + 0.1 % BSA) 16 h after plating. 500 µl medium 
(DMEM/F-12 + Glutamax + horse serum + NGF) was removed, supplemented with the respective 
substance and added back on cells. The stimulation was performed over a time period of 6 hours 
followed by Ca2+-imaging (described above). Ca2+-imaging was performed with the following 
protocol: 1 minute baseline (assay buffer), 2 minutes 30 µM mustard oil (MO), 2 minutes wash out 
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(assay buffer), 2 minutes 100 nM Capsaicin, 2 minutes wash out (assay buffer), 1 minute 60 mM KCl, 
1 minute wash out (assay buffer) (adapted from Willemen et al., 2018). 
3.0 Electrophysiology  
Whole-cell voltage-clamp recordings were performed in order to assess the electrophysiological 
properties (i.e. mechanically activated (MA) currents, membrane potential, amplitude of action 
potential) of DRG neurons from naive TM KO vs. WT mice. For recording of MA currents the cells 
were clamped at -70 mV and mechanically stimulated with fire-polished borosilicate glass pipettes 
(3−5 MΩ resistance). In current-clamp mode, action potentials were recorded using a standard 
current injection protocol. Whole-cell currents and membrane potentials were recorded with an 
EPC10 USB amplifier and the PatchMaster software (HEKA Elektronik) and a piezoelectrically driven 
micromanipulator (Physik Instrumente GmbH&Co.KG) was used for stimulation delivery. 4 µm 
distance to the cell membrane was the starting position of the probe followed by mechanical stimuli 
from 0-6 µm in 1 µm increments. During the ramp phase (forward) the probe velocity was 0.8 µm/ms 
and 150 ms was the time set for stimulus duration (to allow for complete channel adaptation/current 
inactivation). 15 s were used as inter-stimulus interval and a series resistance lower than 10 MΩ was 
the requirement for cells to be considered for analysis. 
Composition of recording solutions:          
Intracellular: 133 mM CsCl, 10 mM HEPES, 5 mM EGTA, 1 mM MgCl
2
, 1 mM CaCl
2
, 4 mM MgATP and 
0.4 mM NaGTP, pH 7.3, osmolarity = 280 mOsm.                                   
Extracellular: 127 mM NaCl, 3 mM KCl, 1 mM MgCl
2
, 2.5 mM CaCl
2
, 10 mM Glucose and 10 mM 
HEPES, pH 7.3, osmolarity = 285 mOsm. Analysis and illustration was performed with FitMaster 
(HEKA) and Igor Pro (WaveMetrics). Experiments were performed by Dr. Pratibha Narayanan  
(according to Avenali et al., 2014, Narayanan et al., 2016).  
3.1 Electron Microscopy (EM)                
SN and DRG were dissected and post-fixed in 4 % fixing solution (Table 7: Tissue Fixation for Electron 
Microscopy, containing Karlsson and Schultz (1965), pH 7.4) for at least for 24 hours. Subsequently, 
tissue of interest was further post-fixed in 2 % osmium tetraoxide, dehydrated and embedded in 
epoxy resin (21.4 g glycid ether, 14.4 g DDSA, 11.3 g MNA, 0.84 ml DMP) (Table 8). Dehydration, 
epon infiltration and polymerization were automatically performed with the ASF II (Leica). Semithin 
(0.5 µm) and ultrathin (50 nm) cross sections of epon embedded SN and DRG were produced with an 
ultramicrotome (Ultracut S, Leica). Methylene blue/Azure II (1 minute) were used to stain sections 
for lipid rich tissue. 1 % uranyl acetate and lead citrate contrasted ultrathin sections. Images were 
taken with the EM912AB electron microscope (Zeiss) with an on-axis 2048 × 2048 charge coupled 
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device camera (Proscan). Experiments performed by me with the equipment and supervision from 
the electron microscopy core unit, MPI EM, PI Dr. Wiebke Möbius (according to Fünfschilling et al., 
2012). 
Table 7: Tissue Fixation for EM  
Components 10 ml fixing solution 
NaH2PO4∙H2O 0.018 g 
Na2HPO4∙2H2O 0.15 g 
NaCl 0.05 g 
A. dest. 5 ml 
Glutaraldehyd (25 %) 1 ml 
Formaldehyd (16 %) 2.5 ml 
A. dest. 1.5 ml 
 
Table 8: Epoxy Resin Embedding for EM  
Substance Time Temperature 
0.1 M Phosphate buffer (PB) 3x 10 min 4°C 
2 % Osmium tetraoxide in 0.1 M PB 4 h 4°C 
0.1 M Phosphate buffer 3x 10 min 4°C 
30 % Ethanol 20 min 4°C 
50 % Ethanol 20 min 4°C 
70 % Ethanol 20 min 4°C 
90 % Ethanol 20 min 4°C 
100 % Ethanol 3x 10 min 4°C 
2-Propanol 10 min 4°C 
Propylene oxide 3x 10 min RT 
2:1 Propylene oxide : Epon 2 h RT 
1:1 Propylene oxide : Epon 2 h RT 
1:2 Propylene oxide : Epon 4 h RT 
Pure Epon 4 h RT 
Transfer to embedding molds Polymerization: 24 h 60°C 
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3.2 Molecular Cloning               
TM cDNA (Origene) was used as a template for cloning. The sequence was obtained from NCBI: 
NM_026938.1 (Mus musculus transmembrane protein 160 (Tmem160), mRNA). Primers were 
designed with BamHI (TTCGTCGACTGGATCCGGTAC) and Eco105I (CGTTACGTATTTAAACCTTATCGTCG
TC) restriction sites to insert the PCR product into the pCMV6 vector for in vitro studies (pCMV6-
TMEM160-Myc-DDK). For generation of TM KO mice a mus musculus BAC clone (AC164880) was 
used as vector for TM HDR.DNA. In order to visualize PCR products, agarose gel electrophoresis was 
performed, and bands excised. DNA purification was performed after manufacturer’s instructions 
(NucleoSpin gel and PCR clean-up kit). Subsequently, insert and vector were digested (FastDigest 
restriction enzymes: BamHI, Eco105I in 1x green buffer, incubation at 37°C, 35 minutes). 
Dephosphorylation of vector by FastAP thermosensitive alkaline phosphatase followed (at 37°C, 35 
minutes, to prevent self-ligation). The reaction was stopped by running the samples on an agarose 
gel. Bands were excised and product purified in the same way as described above. Mixture with T4 
DNA ligase (1 U) in ligase buffer (1x) followed (at 25°C, 2 hours). Afterwards, DH5α E. coli competent 
cells (50 µl) and ligated DNA product (5 µl) was incubated on ice (30 minutes) followed by heat-shock 
transformation (at 42°C, 25 seconds in water bath, 2 minutes on ice). Subsequently, cells were 
incubated (at 37°C, 1 hour, shaking at 250 RPM) after addition of SOC medium (950 µl). 
Centrifugation of cells (6000 rpm, 1 minute), pellet re-suspension (200 µl SOC medium) and plating 
on LB agar plates (containing 100 µg/ml ampicillin) was performed. While shaking (250 rpm) plates 
were incubated overnight (at 37°C). 6 colonies were picked from the LB agar plate and cultured in LB 
medium (5 ml containing 100 µg/ml ampicillin). Overnight incubation followed (at 37°C, shaking 
250 rpm) and finally culture (1 ml) was used for plasmid purification (Pure link HiPure plasmid filter 
maxiprep kit following manufacturer’s instruction). Spectrophotometric analysis was performed to 
assess amount and purity of eluted DNA as well as verification of sequences by sequencing 
(according to Avenali et al., 2014). Performed by Sergej Zeiter and Fritz Benseler (DNA Core Facility 
AGCTLab, MPI EM). 
Table 9: PCR Master Mix Cloning  
Amount (µl) Reagent 
5.0 10x Reaction Buffer 
 
1.5 10 mM dNTPs (each) 
1.0 50 mM MgSO4 
  2. MATERIALS AND METHODS 
 48 





0.4 Polymerase: Platinum PFX 
 
50.0 total  
 
Final concentration: 10x Reaction Puffer 1x, Mg 1.0 mM, dNTPs 0.3 mM each, DNA Pol. 1 U, Primer 
set 0.3 mM each, DNA 150 ng. 
 
Table 10: PCR Cycle Cloning  
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3.3 Mitochondrial Assays 
3.3.1 Enzyme Activity Dipstick (Complex IV)            
The enzyme activity dipstick was used according to manufacturer’s instructions in order to quantify 
the activity of the cytochrome c oxidase (COX) enzyme complex (Complex IV of mitochondrial 
electron transport chain). A COX-specific antibody was immobilized on a dipstick, which enabled 
immuno-capturing of the enzyme complex. DAB (Di-amino benzidinetetrachloride) served as reporter 
of COX activity, meaning the greater the DAB signal (precipitated form) the more COX was present. 
The assay was performed on dissected DRG which were washed in 1x PBS followed by 
homogenization (pestle) in extraction buffer (provided in the kit, ~3 mg/mouse = 60 µl extraction 
buffer. Samples were incubated on ice for 20 minutes and centrifuged (18000 g) for 20 minutes at 
4°C. Afterwards, the supernatant was transferred to a new tube and protein concentration was 
measured with a spectrophotometer. 1/10 volume detergent was added, 25 µg were aliquoted in 
duplicates and filled up with extraction buffer (buffer A) to a volume of 25 µl. A well (96-well 
microplate) was filled with 25 µl buffer A and 25 µl sample. Subsequently, the dipstick was added 
(~30 minutes) and washed by adding 30 µl buffer C. After preparation of activity buffer (1:5:94), 
300 µl were pipetted into a separate empty well for each dipstick (incubation for 45-60 minutes). 
Subsequently, dipsticks were washed for 10 minutes in a well filled with deionized water (300 µl). 
After letting them dry for a few minutes, images were taken followed by analysis with Image J, 
according to manufacturer’s instructions.  
3.3.2 Isolation of Mitochondria          
Tissue of interest (brain, heart, liver) was cut into pieces and homogenized (30x) in THE buffer 
(10 mM KCl, 10 mM Hepes-KOH (pH 6.9), 300 mM Trehalose) with BSA (0.1 %). Homogenizates were 
centrifuged (10 minutes, 4°C, 400 g) and supernatants were collected and re-suspended in THE 
buffer with BSA. Subsequently, the samples were homogenized again and the suspension was 
centrifuged (10 minutes, 4°C, 400 g). Supernatants were saved and spun down (5 minutes, 4°C, 
800 g). The resulting supernatants were centrifuged again (10 minutes, 4°C, 10000 g) resulting in 
pellet formation containing mitochondria. Afterwards the pellet was re-suspended in THE buffer 
without BSA and centrifuged (5 minutes, 4°C, 10000 g). Finally, the resulting pellet was re-suspended 
in the proper amount of THE buffer (depending on pellet size). Protein concentrations were assessed 
with the Bradford analysis (BSA was used as standard). The experiments were either performed by 
Dr. Sven Dennerlein from the Department of Cellular Biochemistry, PI Prof. Dr. Peter Rehling, or by 
me (adapted from Bareth et al., 2016). 
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3.3.3 Seahorse Respiration of Isolated Mitochondria           
The Seahorse XF Analyzer (Seahorse Bioscience, Billerica, MA) is a device, which provides information 
about mitochondrial respiration (oxygen consumption rate (OCR)) and glycolysis (extracellular 
acidification rate (ECAR)). Its basis is a well plate composed of a support plate (equipped with sensor 
cartridges and ports) and a cell plate filled with mitochondria in assay buffer. Each sensor cartridge is 
equipped with two fluorophores (embedded in polymer) at the bottom. One is quenched by O2 and 
the other is sensitive to protons allowing for kinetic measurements (creating a microchamber by 
lowering the sensor cartridge 200 µm above mitochondria). The ports of the support plate allow 
injection of drugs (Oligomycin (4 µM), FCCP (2 µM), Antimycin (2 µM), Rotenone (2 µM), KCN 
(1 mM)). Baseline restoration was allowed whenever the system detects a drop in O2 or H+ by raising 
the sensor cartridge. In detail the ports of the support plate were loaded and kept at 4°C and 
equilibrated for 15 minutes before experiment was started at 37°C. Subsequently, 10x mitochondria 
solution was loaded (18 µl) into the chilled cell plate and spun down (20 minutes at 4°C). Afterwards, 
the instrument was equilibrated and MAS (Mitochondrial assay solution) buffer pipetted into each 
well (162 µl) followed by starting of the seahorse program (Table 15). The experiments were 
performed by Dr. David Pacheu Grau, Department of Cellular Biochemistry, PI Prof. Dr. Peter Rehling 
(adapted from Duggett et al., 2017; Ferrick et al., 2008).  
Table 11: Mitochondrial Assay Solution   
Components Concentration, pH 7.4 
Sucrose 70 mM 
Mannitol 220 mM 
HEPES 2 mM 
KH2PO4 10 mM 
MgCl2 5 mM 
EGTA 1 mM 
BSA 0.2 % 
 
Table 12: Mitochondrial Assay Compounds  
Components Concentration, pH 7.4 
Succinate 1 M 
ADP 80 mM 
Ascorbate 0.2 M 
TMPD 0.1 M 
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Oligomycin 10 mM 
Antimycin A 10 mM 
FCCP 5 mM 
Rotenone 1 mM 
KCN 1 M 
 
Table 13: MAS Complex II  
Components Conc. for 1 ml 10 x Solution in MAS 
Succinate 10 mM 
ADP 4 mM 
Rotenone 1 mM 
 
Table 14: MAS Complex IV  
Components Conc. for 1 ml 10 x Solution in MAS 
TMPD 0.2 mM 
Ascorbate 10 mM 
Antimycin A 4 µM 
 
Table 15: Seahorse Program  

























3.3.4 Blue Native PAGE of Electron Transport Chain Complexes        
Post solubilization (described in 3.3.2) mitochondria were placed on ice (15 minutes) followed by 
centrifugation in order to remove non-soluble material (10 minutes, 4°C, 10000 g). Subsequently, the 
supernatant was transferred to 10x Blue Native (BN) loading dye (5 % Coomassie brilliant blue G-250, 
500 mM 6-aminohexanoic acid, and 100 mM Bis-Tris, pH 7.0). Per lane 65 µl were loaded and 
separated on polyacrylamide gradient gels (4-13 %, 100 V overnight). Finally, the gel was incubated in 
SDS running buffer and blotted (300 mA, 2.5 hours). The experiments were performed by Dr. Sven 
Dennerlein from the Department of Cellular Biochemistry, PI Prof. Dr. Peter Rehling (according to 
Wittig et al., 2006). 
3.3.5 Activity Staining of Electron Transport Chain Complexes              
Activity staining of mitochondrial electron transport chain complexes was performed with 
mitochondria isolated from brain, heart and liver (TM WT vs. KO). After mitochondria solubilization 
(described in 3.3.2), incubation on ice (15 minutes) and centrifugation (10 minutes, 4°C, 10000 g), the 
supernatant was transferred to 10x BN loading dye (5 % Coomassie brilliant blue G-250, 500 mM 6-
aminohexanoic acid, and 100 mM Bis-Tris, pH 7.0). Gel lanes were loaded with 50 µg (CI, CII, CV) or 
100 µg (CIV) mitochondria solution including dye (600 V, 15 mA per gel during the day, until red front 
was running out plus 1 hour). Subsequently, activity staining was performed at 30°C:            
Complex I: gel stripes were incubated for 15 minutes in 30 ml 5 mM Tris / HCl (pH 7.4) and stained in 
30 ml 5 mM Tris/HCl (pH 7.4), 20 mg NBT, 300 µl NADH (stock 100x = 10 mg/ml) (for 30 minutes). 
Complex II: gel stripes were incubated for 15 minutes in 30 ml 5 mM Tris / HCl (pH 7.4) and stained in 
30 ml 5 mM Tris/HCl (pH 7.4), 20 mg NBT, 600 µl Succinate (stock 50x = 1 M), 60 µl PMS (stock 
100 mM in DMSO) (for 30 minutes).                   
Complex IV: gel stripes were incubated for 15 minutes in 30 ml 50 mM KPi (pH 7.2) and stained in 
30 ml 50 mM KPi (pH 7.2), 15 mg DAB, 3 ml cytochrome C (-80°C) (for > 12 hours).             
Complex V: gel stripes were incubated for 2 hours in 35 mM Tris-Base, 220 mM Glycine (TG-buffer: 
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1050 µl 1 M Tris-Base (no pH adjusted), 6600 µl 1 M Glycine (no pH adjusted), H2O to 30 ml (check 
pH with pH-strips) (pH 8.3) and stained in TG buffer, 600 µl ATP (stock 50x = 0.4 M), 420 µl 1 M 
MgSO4, 300 µl Pb(NO3)2 (stock 100x = 20 % w/v) (for a few hours at 30°C). Activities of complexes 
were assessed spectrophotometrically using a Cary 50 Bio UV/Vis spectrophotometer. The 
experiments were performed by Dr. Sven Dennerlein from the Department of Cellular Biochemistry, 
PI Prof. Dr. Peter Rehling (according to Deckers et al., 2014; Wittig et al., 2007). 
3.4 Statistics                   
All statistical analyses were performed with the Graph Pad Prism 8 software (San Diego, CA). The 
two-tailed unpaired Student’s t-test was used for comparisons between two conditions at one time 
point. One-way ANOVA was applied for more than two groups at one testing time point followed by 
Sidak’s Multiple Comparison test. The Friedman test followed by Dunn’s Multiple Comparison test 
was used for different testing time points within the same group (non parametric data). The two-way 
ANOVA was utilized for two or more groups and multiple testing time points followed by Sidak’s 
Multiple Comaprison test. When absolute values were depicted (population proportions: responders 
vs. non-responders Ca2+-imaging) the Fisher’s exact test was employed and the one-sample t-test 
was used for qRT-PCR results (compared to a theoretical value of 1.0). The values are depicted as 
mean ± SEM, N indicates the number of mice, n represents the sample/ cohort number, the 
significance is depicted as asterisk or number sign (* < p 0.05, ** < p 0.01, *** < p 0.001, **** < p 
0.0001 or # < p 0.05, ## < p 0.01, ### < p 0.001, #### < p 0.0001).  
The data depicted in Figure 9 A, was calculated with the median as the data was non parametric. 
However, in order to standardize the illustration of the data I decided to show the mechanical and 
thermal testing results in line with the other data from section 3.1.5 as mean ± SEM. The Friedman 
test followed by Dunn’s multiple comparison tests was chosen as proper statistical test for non 
parametric data (pre vs. post surgery days, only possible within the same genotype). Nevertheless, 
the Friedman test was not suitable for a comparison of several testing days across genotypes. For 
this reason, the 2-way ANOVA followed by Sidak’s Multiple comparison tests was used to assess the 
differences between the mouse lines at all testing days. Even though the 2-way ANOVA was not the 
appropriate test, because it was only suitable for parametric data it appeared robust, because it 
underscored the Friedman test results showing no significant difference in SNI TM KO mice at pre vs. 
POD 7 by indicating a significant difference for SNI TM KO vs. SNI WT (POD 7). 
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3. RESULTS 
3.1 Functional Characterization of TM in Regard to Somatosensation and 
Chronic Pain 
3.1.1 Differential TM Expression during Chronic Pain 
The unbiased proteomics screen (Rouwette et al., 2016) revealed the hitherto uncharacterized 
transmembrane protein Tmem160 (TM). It was shown to be downregulated in DRG after induction of 
inflammatory (CFA model) and neuropathic pain (SNI model) and had not been associated with 
chronic pain before. In order to examine whether TM mRNA levels were comparable to the 
differential regulation on protein level, qRT-PCR was performed. However, TM mRNA was 
upregulated under inflammatory pain conditions in lDRG (lumbar dorsal root ganglia), whereas TM 
levels were decreased in SN (sciatic nerve) after CFA injection as it was seen by proteomics. These 
results were not surprising, given the restricted correlation between mRNA and protein changes, as 
protein variability is the final indicator for gene expression, translation and regulation (Liu et al., 
2016; Schwanhäusser et al., 2011; Sharma et al., 2015). This knowledge was the initial motivation to 
perform the screen for changes on protein level (Rouwette et al., 2016) in order to study the 
molecular underpinnings of chronic pain more accurately. 
                                                     
Figure 5: TM Expression Levels during Inflammatory Pain 
(A, B) qRT-PCR outcomes displayed relative TM mRNA expression levels in lDRG and SN 1 day post CFA 
injection. (A) Increased TM expression in lDRG ipsi compared to lDRG Veh ipsi. A similar trend was seen in lDRG 
ipsi vs. lDRG con. (B) TM mRNA levels were decreased in SN of CFA injected mice. SN CFA ipsi vs. Veh ipsi 
revealed a trend for reduction and SN CFA ipsi vs. CFA con indicated a significant downregulation. Number of 
animals in column; data collected from several independent experiments; the one sample t-test; ** p < 0.01. 
Data were represented as mean ± SEM. lDRG, lumbar dorsal root ganglia; SN, sciatic nerve; ipsi, ipsilateral; con, 
contralateral; CFA, Complete Freund’s Adjuvant; Veh, vehicle. 
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3.1.2 Localization of TM in Mitochondria 
TM has a theoretical topology of 3 transmembrane domains (TMD, Figure 6 A) and bioinformatics 
analyses suggested a mitochondrial localization (Uniprot, https://www.uniprot.org/uniprot/Q9D938). 
Further investigation of the amino acid sequence revealed a 98.68 percent probability for TM to be 
exported from the cytosol to mitochondria (signal peptide for import indicated in Figure 6 A, 
MitoProt II - v1.101, https://ihg.gsf.de/ihg/mitoprot.html, Claros and Vincens, 1996). The unbiased 
proteomics screen (Rouwette et al., 2016) was performed on membrane enriched lumbar DRG 
(lDRG) lysates. The obtained membrane proteins were expressed in sensory neurons and additional 
cell types of DRG (e.g. peripheral glial cells and diverse immune cells). Therefore, I investigated the 
localization of TM in sensory neurons (DRG culture, Figure 6 C) and Schwann cells (SC, peripheral glial 
cells, Figure 6 D) by overexpression and immunolabeling (latter experiments performed by Dr. Luca 
Avenali (former colleague) and Dr. Susanne Quintes, Department of Neurogenetics, PI Prof. Klaus-
Armin Nave, Ph.D). Furthermore, TM was overexpressed and labeled in HEK293 cells (Figure 6 B) in 
order to examine whether it was ubiquitously expressed in mitochondria. The hypothesis could be 
proofed for all investigated cell types.  
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Figure 6: Ubiquitous TM Expression in Mitochondria 
(A) TM protein organization with predicted signal peptide (indicated in pink) for import from cytosol into 
mitochondria and transmembrane domains (TMD 1-3 depicted in blue, orange, green; numbers indicate amino 
acid residues). (B-D) Representative immunocytochemistry for co-labeling of TM (myc staining) with 
mitochondrial markers. (B) HEK293 cell culture, (C) DRG culture and (D) SC culture (latter experiments 
performed by Dr. Luca Avenali (former colleague) and Dr. Susanne Quintes, Department of Neurogenetics, PI 
Prof. Klaus-Armin Nave, Ph.D) transfected with 0.5 µg TM-myc-plasmid (pCMV6-TMEM160-Myc-DDK) depicted 
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in magenta. Co-staining with mitochondrial markers shown in cyan (HEK293 cell culture: Ndufv2 
(NADH:ubiquinone oxidoreductase core subunit v2, subunit CI), DRG culture: 0.5 µg HyPer-mito-YFP plasmid 
(kindly provided by Department of Metabolic and Redox Signaling, PI Prof. Dr. Michael Müller), SC culture: 
Mitotracker) showed TM localization in mitochondria. N = several coverslips from 3 independent HEK293 cell 
cultures; scale bar, 10 µm. N = several coverslips from 4 independent DRG cultures; scale bar, 10 µm. N = 
several coverslips from 2 independent SC cultures; scale bar, 5 µm. DRG, dorsal root ganglia; SC, Schwann cells. 
 
3.1.3 Successful Generation of TM KO Mice 
In order to assess the relevance of TM in vivo, KO mice were generated by deletion of Exon 1 (Figure 
7). The CRISPR/Cas9 technology (in collaboration with the DNA core and transgenic facilities of the 
MPI EM) was used to insert the loxP sites for conditional TM removal. TM was shown to be 
expressed in sensory neurons and SC. Therefore, respective KO lines were bred, composed of a 
constitutive KO line (cTMEM160_cKO r/r x Ella Cre = referred to as TM KO), a SC specific KO line 
(cTMEM160_cKO r/r x Dhh Cre = referred to as cKO in SC) and a sensory neuron specific KO line 
(cTMEM160_cKO r/r x Advillin Cre = referred to as cKO in SeN). Successful TM deletion in the sensory 
neuron specific KO was validated by genotyping. For the constitutive and SC specific KO, qRT-PCR and 
in situ hybridization (ISH) (RNAscope 2.5 HD Detection Kit) were performed in addition for validation 
purposes (Figure 7). The ISH results showed an equal TM mRNA expression in DRG subpopulations of 
WT mice, which was in line with RNA sequencing data from (Usoskin et al., 2015). In addition, I could 
show TM expression in SC. 
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Figure 7: Successful Generation and Validation of TM Deletion in KO Mice 
(A) Schematic illustration of TM WT, TM floxed and TM sequence after recombination. The homology-directed 
repair (HDR) fragment, including PAM sites (black), single guide RNA target nucleotides (green), lox P sites 
(orange) and Exons (pink) is marked with a black bar. Not drawn to scale. (B, C) qRT-PCR results showed relative 
TM expression normalized to Actin. (B) 99 % decrease of TM expression in DRG of constitutive KO mice and 70 
% TM reduction in SC specific KO’s. (C) Reduction of TM levels in SN of constitutive KO’s to 99 % and in SC 
specific KO’s to 95 %. (D, E) Representative images of in situ hybridization on WT DRG and WT SN cross-sections 
showed TM expression in all sensory neurons of DRG and in SC of SN. Declined TM mRNA staining in 
constitutive and SC specific KO’s underscores qRT-PCR results. WT: TM wt Ella cre tg, female, 7w; KO: TM r/r 
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Ella cre tg, female, 7w; fl/fl in SC: TM wt Dhh tg, female, 7w; cKO in SC: TM r/fl Dhh tg, female, 7w; Dhh (Desert 
hedgehog) cre: SC specific KO (recombination E11-E13.5); Ella cre: constitutive KO: recombination E0.5. 5 µm 
paraffin slices, 50 % hematoxylin to stain nuclei. qRT-PCR: Number of animals in column; data collected from 
several independent experiments; in situ hybridization: N = 1-2 mice; scale bar, 100 µm (inset, 50 µm); the one 
sample t-test; *** p < 0.001. Data were represented as mean ± SEM. DRG, dorsal root ganglia; SC, Schwann 
cells; SN, sciatic nerve; HDR, homology-directed repair; PAM site, protospacer adjacent motif; gRNA, guide 
RNA. 
3.1.4 No Myelination Deficit in Consequence of TM Removal     
After the successful generation of TM KO mice the general wellbeing (birth rate, size, weight) and 
motor coordination (latter investigated with the Rotarod device) of the transgenic mice were 
assessed. A longitudinal investigation (age 8-19 and 32-46 weeks) revealed intact motor abilities 
(Figure 8 A), which were in line with no major changes in myelin and SC markers in SN examined via 
qRT-PCR (Figure 8 B). Further analysis of the myelin sheath by electron microscopy (Figure 8 C) and 
induction of myelination in SC-DRG coculture (Figure 8 D-F) showed no abnormalities and therefore 
underscored the behavioral results.  
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Figure 8: No Hint for Myelination Deficit in TM KO Mice 
(A) Longitudinal investigation of TM KO mice (8-46 weeks) revealed no motor impairment. Number of animals 
in column; n = 4 independent cohorts; 2-way ANOVA followed by Sidak’s multiple comparison tests. Data were 
represented as mean ± SEM. (B) qRT-PCR results showed relative expression of myelin and SC markers 
normalized to GAPDH. No major changes in mRNA levels of MBP, MPZ, S100b and GFAP in SN of TM KO mice. 
Number of animals in column; data collected from several independent experiments; the one sample t-test; * p 
< 0.05. Data were represented as mean ± SEM. (C) Representative electron microscope images showing no 
overt changes in myelin sheath ultrastructure in SN of TM KO compared to WT mice. WT N = 2; KO N = 2; Scale 
bar, 2.5 µm. (D-F) Similar number of MBP segments in SC-DRG coculture upon induction of myelination 
compared between genotypes. Number of independent cultures in column, several coverslips/ culture; 
unpaired student’s t-test. Data were represented as mean ± SEM; scale bar, 20 µm. DRG, dorsal root ganglia; 
SN, sciatic nerve; SC, Schwann cells; MBP, myelin basic protein; MPZ, myelin protein zero; S100b, calcium 
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binding protein B expressed in SC (promyelination factor); GFAP, glial fibrillary acidic protein (marker for 
immature SC, negative regulator of SC differentiation); Tuj1, β-Tubulin 3. 
 
3.1.5 TM Deletion results in Pain Modality specific Analgesia 
A battery of behavioral paradigms was performed in order to investigate the role of TM in regard to 
PNS (peripheral nervous system) function and pain pathology. Intact gait properties of TM KO mice 
were shown with the Catwalk system (experiments performed by Dr. Daniel Segelcke, Group of 
Translational Pain Research, PI Prof. Esther Pogatzki-Zahn) (Figure 9 H, J, L, N Sham values). 
Moreover, no difference in basal mechanical and thermal (heat) sensitivity as well as non-evoked 
pain could be shown in healthy TM KO mice (Figure 9 B, D, F Sham values). Given the comprehensive 
proteome profiling (Rouwette et al., 2016), which showed a downregulation of TM under 
inflammatory and neuropathic pain conditions, these pain entities were induced in TM KO and WT 
littermates. Induction of neuropathic pain conditions (SNI model) and behavioral testing was 
performed by Dr. Daniel Segelcke (Figure 9). Inflammatory pain was induced by CFA injection in both 
mouse lines followed by behavioral phenotype investigation (mechanical and thermal testing 
performed by me, Figure 9 A, B; non-evoked pain and assessment of gait properties carried out by 
Dr. Daniel Segelcke, Figure 9 C-G). Interestingly, TM KO mice showed a significantly reduced tactile 
hypersensitivity under early neuropathic pain conditions (post operation day (POD) 7), when 
inflammation was most prominent (Cobos et al., 2018a). However, hypersensitivity at POD 14, POD 
21 and POD 28 was not different compared to WT littermates (Figure 9 A, B). Furthermore, no major 
changes (no biological relevance for decreased withdrawal latency at POD 21 in SNI TM KO, because 
no significant difference among genotypes) in the reaction to a heat stimulus could be examined 
during all assessed testing days (Figure 9 C-D). WT mice did not show thermal hypersensitivity after 
induction of neuropathic pain. This pain modality is a less constant index for nociceptive responses 
after SNI than mechanical hypersensitivity (Decosterd and Woolf, 2000; Koltzenburg, 1998). In 
addition, the investigation of non-evoked pain revealed a similar decrease in the ratio of paw contact 
area (operated/non-operated paw) compared to pretesting values among genotypes (Figure 9 E, F).  
Moreover, movement-evoked pain was assessed with the Catwalk system (Noldus), capable for the 
investigation of a dozen gait parameters. Pitzer et al. showed 6 specific parameters affected by 
neuropathic pain (SNI model) (Pitzer et al., 2016b). Based on this study our collaboration partner Dr. 
Daniel Segelcke decided to investigate the mentioned key features (4 of them depicted in Figure 9 
(SNI model) and in Figure 10 (CFA model, mentioned below in detail)). The 4 illustrated parameters 
were static (print area: surface of the complete print of a paw; stand: duration of ground contact for 
a single paw) and dynamic parameters (swing speed: velocity (distance/ time) when the paw was not 
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in contact with the glass plate; duty cycle: duration of paw contact divided by time between 
consecutive paw contacts). The analysis revealed a similar decrease in the ratio for all investigated 
static parameters among genotypes after induction of neuropathic pain compared to pretesting 
values (Figure 9 G-J). However, dynamic parameters were improved in SNI TM KO mice compared to 
pretesting values (Figure 9 K-N). Nevertheless, a biological relevance was not hypothesized given that 
no significant difference among genotypes was shown for all tested gait features (Figure 9 G-N). 
Furthermore, in addition to TM KO mice inflammatory pain was also evoked in TM cKO in SeN (TM 
KO in sensory neurons) allowing for assessment of cell type specific TM contribution to 
somatosensory behaviors. Remarkably, both KO lines showed an impairment of mechanical 
hypersensitivity during inflammatory pain (analgesia) at day 1 and 3 post CFA injection (TM KO, 
Figure 10 A) and at day 1 post CFA (TM cKO in SeN, Figure 12 A), while thermal hypersensitivity was 
unaffected in both KO lines (TM KO: Figure 10 B, TM cKO: Figure 12 B). It was unusual to detect 
mechanical hypersensitivity only at 1 day post CFA but not at 3 days post CFA in WT littermates of 
TM cKO mice (Figure 12 A). I expected to investigate the effect also at 3 days post CFA as WT 
littermates of TM KO mice showed mechanical hypersensitivity (Figure 10 B). However, biological 
variability of mice and the use of different CFA batches could lead to shortened mechanical 
hypersensitivity in WT littermates in Figure 12 A. It was also noticeable, that the thermal 
hypersensitivity was present in TM WT and KO mice even after 6 days post CFA (Figure 10 B), 
whereas this hypersensitivity was only revealed at post CFA day 2 in the WT littermates of TM cKO 
mice (Figure 12 B). Nevertheless, the slight difference in CFA effectiveness did not negate the fact 
that TM KO as well as TM cKO showed decreased mechanical hypersensitivity and intact thermal 
hypersensitivity compared to WT controls (Figure 10 A, B and Figure 12 A, B). As investigated during 
chronic pain (Figure 9), CFA-treated TM KO mice were additionally investigated for potential 
alterations in other pain modalities. Non-evoked pain testing showed similar results for TM WT and 
KO mice (Figure 10 C) as well as in regard to movement-evoked pain (Figure 10 D-G). However, it is 
important to mention that there was no significant reduction in the ratio of all assessed static and 
dynamic parameters in WT mice injected with CFA (1-14 days post CFA vs. pretesting values). 
However, Pitzer et al. could show a decrease in static gait parameters (e.g. print area and paw 
pressure) in the CFA model. These values were investigated with the dynamic weight bearing (DWB) 
and the Catwalk system revealing a high degree of comparability (Pitzer et al., 2016a). Other studies 
underscored the results as they indicated a similar decrease in static parameters with the DWB 
system upon CFA injection (Cobos et al., 2012; Huntjens et al., 2009). Additionally, Pitzer et al. were 
able to demonstrate alterations in dynamic gait parameters in the CFA model with the Catwalk 
system and claimed the detailed gait analysis as important paradigm to assess changes upon 
inflammation (Pitzer et al., 2016a). However, we were not able to reproduce those findings with our 
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mouse models. Possible explanations could be different mouse strains (Pitzer et al. used C57BL/6N 
mice), the pain model (Pitzer et al. injected 10 µl CFA more) or the investigation time point (Pitzer et 
al., 2016a). Nevertheless, most importantly, no significant difference among genotypes was revealed 
for all tested days (Figure 10 D-G). Furthermore, the investigated behavioral phenotype of TM KO 
mice was specific for chronic pain conditions, as physiological pain assessed by the injection of the 
TRPV1 agonist capsaicin elicited mechanical hypersensitivity and acute pain behavior (time spent 
licking, flicking and lifting of the paw) equally in TM KO and WT mice (Figure 11). 
Collectively, these results suggested a modality-specific TM involvement in inflammatory signaling 
pathways during early neuropathic and inflammatory pain. It was shown that a sensory neuron 
specific TM KO was sufficient to evoke the same phenotype during inflammatory pain as investigated 
in the constitutive TM KO. 
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Figure 9: Pain-Modality Specific Phenotype after TM Deletion in Vivo 
TM KO mice revealed no mechanical hypersensitivity during neuropathic pain (7 days post SNI), whereas 
thermal sensitivity was unaltered. (A-N) Behavioral paradigms performed with SNI and Sham mice. (A) 
Mechanical hypersensitivity attenuation in TM KO SNI model at POD 7 compared to pretesting values (when 
inflammation was most prominent (Cobos et al., 2018)). Significant difference between genotypes at POD 7. (B) 
Sham mice did not show overt mechanical hypersensitivity. (C, D) No major change in thermal sensitivity in 
both genotypes after SNI and Sham. (E, F) Unimpaired NEP behavior in TM KO mice. (G-N) Movement-evoked 
pain assessed by the catwalk paradigm revealed slightly improved gait properties in TM KO mice after SNI 
surgery compared to pretesting values, but no significant difference between genotypes. (A-N) Experiments 
performed by Dr. Daniel Segelcke, Group of Translational Pain Research (PI Esther Pogatzki-Zahn). WT SNI N = 
12; KO SNI N = 9; n = 3 independent cohorts; WT Sham N = 6; KO Sham N = 10; n = 4 independent cohorts; (A, 
B) the Friedman test followed by Dunn’s multiple comparison tests; * p < 0.05 vs. pre, ** p < 0.01 vs. pre, *** p 
< 0.001 vs. pre; **** p < 0.0001 vs. pre; 2-way ANOVA followed by Sidak’s multiple comparison tests; #### p < 
0.0001 WT vs. KO. Data were represented as mean ± SEM. (C-N) 2-way ANOVA followed by Sidak’s multiple 
comparison tests; * p < 0.05 vs. pre, ** p < 0.01 vs. pre, *** p < 0.001 vs. pre; **** p < 0.0001 vs. pre; # p < 
0.05 WT vs. KO. Data were represented as mean ± SEM. SNI, spared nerve injury; Sham, Sham nerve injury; 
NEP, non-evoked pain; RH, right hind paw = operated paw.  
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Figure 10: Diminished Mechanical Hypersensitivity upon TM Elimination 
(A) Mechanical sensitivity was attenuated in TM KO mice 1 and 3 days (ipsi vs. con) post induction of 
inflammatory pain (CFA injection), whereas no behavioral alterations were found between genotypes under 
naive conditions (depicted by pretesting results). (B) WT and KO mice reacted with hypersensitivity to thermal 
stimulus 2 and 6 days post CFA injection (ipsi vs. con and ipsi vs. pre). No alteration between testing groups in 
withdrawal latency upon heat application during pretesting (naive condition). (C) Similar results for NEP testing 
among genotypes after CFA injection. (D-G) Catwalk paradigm revealed no significant changes of movement-
evoked pain between WT and KO mice 1-14 days post CFA injection. (A, B) WT N = 13; KO N = 10; n = 3 
independent cohorts. (C-G) Experiments performed by Dr. Daniel Segelcke, Group of Translational Pain 
Research (PI Esther Pogatzki-Zahn). WT N = 10; KO N = 7; n = 1 cohort. (A-G) 2-way ANOVA followed by Sidak’s 
multiple comparison tests; * p < 0.05 vs. pre, ** p < 0.01 vs. pre, *** p < 0.001 vs. pre; **** p < 0.0001 vs. pre; 
## p < 0.01 ipsi vs. con, ### p < 0.001 ipsi vs. con,  #### p < 0.0001 ipsi vs. con. Data were represented as mean 
± SEM. CFA, Complete Freund’s Adjuvant; ipsi, ipsilateral; con, contralateral.  
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Figure 11: Capsaicin-evoked Acute Pain unchanged among Genotypes 
(A) WT and KO mice showed a similar mechanical hypersensitivity upon induction of acute pain (10-90 minutes 
post injection of the TRPV1 agonist capsaicin). WT N = 15; KO N = 17; n = 2 independent cohorts; 1-way ANOVA 
followed by Sidak’s multiple comparison tests; #### p < 0.0001 ipsi vs. con. (B) Comparable results between 
genotypes in time spent flicking, lifting and shaking of the injected paw (0-10 minutes post injection). WT N = 
15; KO N = 17; n = 2 independent cohorts; unpaired student’s t-test. Data were represented as mean ± SEM. 
Ipsi, ipsilateral; con, contralateral.  
 
 
Figure 12: Sensory Neuron-specific TM KO sufficient to evoke impaired CFA-mediated Mechanical 
Hypersensitivity  
(A) Analgesia upon TM deletion in vivo in regard to mechanically evoked pain shown as gram needed to elicit 
paw withdrawal. Compared to WT mice TM cKO’s did not show mechanical hypersensitivity at 1 day post CFA 
injection (ipsi vs. con). The withdrawal force in TM cKO’s was significantly increased compared to WT mice (1 
day post CFA, ipsi). (B) No apparent alteration in reaction to thermal stimulus in cKO mice. Both mouse lines 
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showed thermal hypersensitivity 2 days post CFA injection (ipsi vs. con and ipsi vs. pre).  WT N = 12-13; cKO N = 
14; n = 2 independent cohorts; 2-way ANOVA followed by Sidak’s multiple comparison tests; * p < 0.05 vs. pre, 
*** p < 0.001 vs. pre; **** p < 0.0001 vs. pre; # p < 0.05 ipsi vs. con, # p < 0.05 WT vs. KO, ## p < 0.01 ipsi vs. 
con. Data were represented as mean ± SEM. Ipsi, ipsilateral; con, contralateral.  
3.1.6 Study of Neuronal Expression/ Excitability after TM Elimination 
3.1.6.1 Similar PNS Protein Expression in TM KO Mice 
 
To gather more information on the impact of TM in respect to chronic pain and PNS (peripheral 
nervous system) functions, I studied the abundance and expression pattern of PNS proteins 
(commonly used markers like peripherin for nociceptors and NF200 for myelinated neurons, 
according to Avenali et al., 2014) in naive and CFA-injected (1 day post) TM KO and WT mice. More 
precisely, the percentage and intensity of peripherin and NF200 positive neurons was investigated in 
naive and CFA-treated (1 day post, ipsilateral vs. contralateral injection side) TM KO and WT mice 
(lDRG). The investigation of TM KO tissue revealed a similar expression of peripherin and NF200 
under naive conditions (Figure 13) as well as after induction of chronic pain (Figure 14). Previous 
work from Rouwette and colleagues (Rouwette et al., 2016) showed an increased peripherin 
expression in WT mice after CFA injection (1 d post). However, the difference could be mouse strain 
dependent as Rouwette et al. analyzed tissue of C57/Bl6 WT mice, whereas I used TM WT littermates 
in comparison to TM KO mice. The only detectable difference was a decreased NF200 intensity in 
lDRG WT ipsi and lDRG KO con compared to lDRG WT con (Figure 14). This result could be explained 
by the unusual high NF200 intensity in lDRG WT con that might be caused by a staining artifact.  
All in all, TM deletion did not cause alterations of different neuronal populations (nociceptors vs. 
large myelinated neurons).    
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Figure 13: No Difference in Expression of Neuronal Populations in DRG of naive TM KO Mice 
Representative immunohistochemistry for peripherin and NF200 expressed in DRG of naive mice and analysis 
in regard to percentage of neurons positive for respective marker as well as fluorescence intensity. Neither the 
percentage nor the fluorescence intensity of both marker proteins differed between DRG of WT and TM KO 
mice. Number of animals in column; WT (3 cryoblocks, in each DRG of 2 mice); KO (2 cryoblocks with DRG of 1 
or 2 mice); each); several staining rounds; each block was cut in 10 µm thick tissue sections and 7 DRG sections 
were analyzed; unpaired student’s t-test. Data were represented as mean ± SEM; scale bar, 100 µm. DRG, 
dorsal root ganglia; Peripherin, marker for nociceptors; NF200, neurofilament 200, marker for large myelinated 
neurons. 
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Figure 14: Similar Neuronal Population Expression in DRG of CFA-treated TM KO Mice 
Representative immunohistochemistry of both neuronal marker proteins of DRG from mice injected with CFA 
(sacrificed 1 day post injection). Analysis revealed no overt alteration in percentage of marker expression and 
fluorescence intensity. Unusual high NF200 intensity in WT DRG con caused significant difference to WT DRG 
ipsi and KO DRG con. Number of animals in column; several staining rounds; WT (3 cryoblocks, in each DRG of 1 
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mouse); KO (3 cryoblocks with DRG of 1 mouse); each block was cut in 10 µm thick tissue sections and 7 DRG 
sections were analyzed; 1-way ANOVA followed by Sidak’s multiple comparison tests; * p < 0.05, ** p < 0.01. 
Data were represented as mean ± SEM; scale bar, 100 µm.  DRG, dorsal root ganglia; Peripherin, marker for 
nociceptors; NF200, neurofilament 200, marker for large myelinated neurons; ipsi, ipsilateral; con, 
contralateral; CFA, Complete Freund’s Adjuvant.  
3.1.6.2 Steady Neuronal Excitability in DRG of TM KO Mice 
 
Based on the in vivo data, which showed similar results in TM KO and WT littermates in regard to 
basal mechanical and thermal sensitivity (3.1.5), I aimed to gain insights into functional properties of 
my protein of interest. It was known that in vivo findings correlate with many features of primary 
DRG neuron cultures (Avenali et al., 2014; Sondermann et al., 2018). Therefore, the consequences of 
TM deletion were studied in the DRG culture in vitro-system to examine potential differences in 
sensory neuron physiology. To this end firing properties (e.g. mechanically activated (MA) currents, 
action potential amplitude) were evaluated among genotypes with electrophysiological experiments 
(current-clamp mode, performed by Dr. Pratibha Narayanan, former colleague). No overt changes 
were detected in terms of rapid adapting currents and mean amplitudes of action potentials in 
sensory neurons from TM KO’s compared to WT mice (Figure 15 A, B).  
 
Figure 15: Electrophysiological Investigation revealed no Major Changes in Neuronal Excitability 
after TM Removal 
(A) No difference of rapid adapting currents in sensory neurons of TM KO compared to WT mice. WT N = 4; KO 
N = 4; WT displacement (µm) 0: 18.44 ± 10.91, n = 25; 1: 103.76 ± 48.78, n = 25; 2: 485 ± 255.70, n = 25; 3: 
1088.72 ± 587.21, n = 25; 4: 1198.71 ± 373.51, n = 24; 5: 2737.83 ± 831.78, n = 24; 6: 3130.68 ± 961.38, n = 22. 
KO displacement (µm) 0: 29.12 ± 28.53, n = 25; 1: 128.48 ± 105.41, n = 25; 2: 397.72 ± 237.35, n = 25; 3: 
1140.64 ± 729.45, n = 25; 4: 466.30 ± 116.43, n = 23; 5: 1945.26 ± 606.62, n = 23; 6: 2234.48 ± 713.57, n = 21; 2-
way ANOVA followed by Sidak’s multiple comparison tests. Data were represented as mean ± SEM. (B) Mean 
action potential amplitude showed no difference between genotypes. WT N = 4; KO N = 4; WT mean amplitude 
of AP: 110.255 ± 8.79, n = 15; KO mean amplitude of AP: 121.52 ± 7.57, n = 16; unpaired student’s t-test. Data 
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were represented as mean ± SEM. The experiments were performed by Dr. Pratibha Narayanan, former 
colleague. RA, rapid adapting; pA, picoampere; AP, action potential. 
The calcium-permeable transient receptor potential (TRP) channel family is known to be implicated 
in nociceptive signaling (Bourinet et al., 2014; Patapoutian et al., 2009). Therefore, I wanted to 
investigate whether TRPV1 (noxious heat detector ~43°C (Caterina et al., 1997; Julius, 2013; 
Tominaga et al., 1998)) and TRPA1 (3.1.10.2, involved in mechanical hypersensitivity (Kwan et al., 
2006; Petrus et al., 2007)) mediated calcium influx was altered in sensory neurons of TM KO mice. 
The calcium imaging results (mainly carried out by my Master student Hanna Kristina Fischer, taught 
and supervised by me) revealed an unchanged neuronal excitability as it was seen by 
electrophysiological experiments (Figure 15). More precisely, neither calcium signals upon TRPV1 
activation assessed as percentage of responders to different stimuli (100 nM Capsaicin (TRPV1 
agonist), 1 µM Capsaicin (increased concentration of TRPV1 agonist), 60 mM KCl (neuronal activity)) 
and the mean peak response amplitude were different between genotypes (Figure 16 A-C).          
Together, these in vitro findings supported the unmodified somatosensory (thermal and mechanical 
sensitivity) behaviors in naive TM KO mice.  
  




Figure 16: TM Deletion caused no Change in Neuronal Excitability as examined by Ratiometric 
Calcium Imaging 
(A) Representative traces (35 neurons) of calcium increase measured by Ca2+-imaging of dissociated DRG 
cultures from naive WT and TM KO mice. 3 pulses were applied (100 nM Caps, 1 µM Caps, 60 mM KCl) and 
amplitudes (peak of fluorescence ratio 340/380 above baseline) were quantified. (B) Mean response 
amplitudes revealed similar results for WT and TM KO sensory neurons after stimulation with 3 pulses. Cell 
count in columns; WT N = several coverslips from n = 4 independent cultures; KO N = several coverslips from n 
= 4 independent cultures; n = 1 imaging round performed by me and n = 3 performed by my Master student 
Hanna Kristina Fischer, taught and supervised by me; unpaired student’s t-test. Data were represented as 
mean ± SEM. (C) Stacked bar graphs illustrate the fraction of responders (colored) and non-responders (white). 
Count of total number of neurons in columns; WT N = several coverslips from n = 4 independent cultures; KO N 
= several coverslips from n = 4 independent cultures; n = 1 imaging round performed by me and n = 3 
performed by my Master student Hanna Kristina Fischer, taught and supervised by me; the Fisher exact test. 
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3.1.7 Screen for Molecular Changes upon TM Deletion 
3.1.7.1 Pronounced Regulation of Mitochondrial Components and Inflammatory Mediators 
in TM KO Mice  
 
As mentioned in the introduction it was known that diverse pathological pain conditions are 
characterized by mitochondrial dysfunction (Baloh et al., 2008; Fernyhough et al., 2010; Joseph et al., 
2009; Osio et al., 2006; Rouwette et al., 2016). These could be caused by activity/ expression changes 
of the electron transport chain (ETC) (Baloh et al., 2008; Fernyhough et al., 2010; Joseph et al., 2009; 
Osio et al., 2006), increased reactive oxygen species (ROS) leading to oxidative stress (Kim et al., 
2004) and microglia activation (Kallenborn-Gerhardt et al., 2013), as well as an unbalanced calcium 
homeostasis (Shishkin et al., 2002). In order to test whether TM was involved in mitochondrial 
dysfunction, I started with the investigation of expression levels from ETC components. Furthermore, 
given that TM seemed to serve as pro-algesic factor during inflammatory pain conditions in vivo, I 
wanted to examine for altered expression of prototypic inflammatory mediators (3.1.5). All KO values 
shown in Figure 17 were normalized to respective WT values before (WT values set at 1, not shown 
in Figure; Figure 17 A-F). Ipsi values were normalized to con values of the same genotype (Figure 17 
G-H, con values not shown in graph). TM KO and WT mice were assessed for differential gene 
expression by qRT-PCR under naive and chronic pain conditions. Interestingly, prominent mRNA level 
changes were mainly detectable in DRG of naive TM KO mice. In detail, 3 subunits of the 
mitochondrial ETC were differentially expressed (Cox1, cytochrome c oxydase c1 (Complex IV) 
downregulated; ND2, subunit of NADH dehydrogenase (Complex I) downregulated; Uqcr10, 
ubiquinol-cytochrome c reductase, complex III subunit X (Complex III) upregulated) in DRG of naive 
TM KO mice (Figure 17 A). In addition, the mitochondrial transcription factor A (Tfam) was decreased 
in the same tissue (Figure 17 A). Furthermore, the qRT-PCR results for inflammatory markers 
revealed a decrease in TNF α (tumor necrosis factor alpha) (Figure 17 B, assessed in TM KO DRG) and 
CCl2 (chemokine (C-C motif) ligand 2) expression (Figure 17 D, examined in TM KO SN). 
Taken together, these findings indicated the involvement of TM in mitochondrial (dys)function and 
inflammatory signaling.           
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Figure 17: Altered Mitochondrial and Inflammatory Gene Expression in TM KO Mice 
(A-H) qRT-PCR results showed relative expression of diverse mitochondrial and inflammatory genes normalized 
to GAPDH. (A-D) Altered gene expression in lDRG and SN of naive TM KO’s referred to WT values (not shown, 
set to expression level of 1). (A) Relative expression levels in KO lDRG showed Cox1, ND2 and Tfam decrease 
and an Uqcr10 increase. (B) TNFα levels were down-regulated in lDRG of TM KO’s. (C) KO SN revealed no 
expression changes in regard to tested mitochondrial genes. (D) Relative CCl2 expression was decreased in SN 
of TM KO mice. (E-F) Investigation of mRNA levels in lDRG and SN of WT and KO mice 1 day post CFA injection 
(KO values compared to WT values which were not shown, set to relative expression level of 1). (E) No 
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significant difference in lDRG gene expression post CFA. (F) Cox1 and Iba1 levels were decreased in SN CFA KO 
con compared to SN CFA WT con and ND2 expression was increased in SN CFA KO ipsi compared to CFA WT 
ipsi. (G-H) Relative expression level changes of lDRG and SN from CFA WT ipsi vs. CFA KO ipsi (CFA WT ipsi 
values compared to CFA WT con and CFA KO ipsi values related to CFA KO con before; con values not shown, 
relative expression set as 1). (G) No significant changes in lDRG CFA KO ipsi mRNA of investigated candidates. 
(H) SN revealed no overt alterations in CFA KO ipsi gene expression. Number of animals in column; data 
collected from several independent experiments; (A-F) one sample t-test, * p < 0.05, ** p < 0.01, **** p < 
0.0001; (G-H) unpaired student’s t-test. Data were represented as mean ± SEM. Cox1, cytochrome c oxydase c1 
(Complex IV); ND2, subunit of NADH dehydrogenase (Complex I); Cytb, cytochrome b; Uqcr10, ubiquinol-
cytochrome c reductase, complex III subunit X; Tfam, mitochondrial transcription factor A; TNFα, tumor 
necrosis factor alpha; CCl2, chemokine (C-C motif) ligand 2; c-Jun, Jun proto-oncogene AP-1 transcription factor 
subunit; Iba1, ionized calcium-binding adapter molecule 1. lDRG, lumbar dorsal root ganglia; SN, sciatic nerve; 
ipsi, ipsilateral; con, contralateral; CFA, Complete Freund’s Adjuvant. 
 
3.1.8 Investigation of Mitochondrial Function Upon TM Deletion 
Motivated by the altered ETC component expression (3.1.7), I wanted to explore the hypothesis of 
TM involvement in mitochondrial dysfunction in more detail. To this end, our collaboration partners 
and me performed a number of experiments in order to investigate mitochondrial protein 
abundance, ETC component activities, oxygen consumption rate and mitochondrial membrane 
potential. All of the evaluated parameters were similar among tissue isolated from TM KO and WT 
mice.   
3.1.8.1 No Overt Abundance Changes of Mitochondrial Proteins 
 
Mitochondria were isolated from brain, heart and liver of both mouse lines (adapted from Bareth et 
al., 2016), because previous studies revealed that DRG of 10 mice would be needed in order to 
extract a sufficient amount of mitochondria. Blue native PAGE (BN-PAGE) was performed for 
segregation of the mitochondrial ETC multiprotein complexes followed by western blotting. Protein 
abundance was tested subsequently by applying antibodies directed against subunits of ETC 
complexes I-V. No overt changes were detected among ETC subunit proteins among the investigated 
tissue between genotypes. The experiments were performed by Dr. Sven Dennerlein, Department of 
Cellular Biochemistry, PI Prof. Dr. Peter Rehling. 
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Figure 18: No Major Protein Abundance Change in ETC Subunits of TM KO Brain, Heart and Liver 
Representative image of western blot results of BN-PAGE showed minor variations (in mitochondria of TM KO 
brain slightly reduced) in mitochondrial protein expression across genotypes. Isolated mitochondria from brain, 
heart and liver of TM WT and KO mice were used for the experiment. N = 4 mice; 4 independent experiments. 
The experiments were performed by Dr. Sven Dennerlein, Department of Cellular Biochemistry, PI Prof. Dr. 
Peter Rehling. NDUFA10, NADH:ubiquinone oxidoreductase subunit a10 (Complex I); SDHA, succinate 
dehydrogenase complex flavoprotein subunit A (Complex II); Rieske, ubiquinol-cytochrome c reductase, rieske 
iron-sulfur polypeptide 1 (UQCRFS1, Complex III); COX1, cytochrome c oxidase c1 (Coomplex IV), ATP5B, ATP 
synthase f1 subunit beta (Complex V). 
3.1.8.2 Similar Activity Levels of Electron Transport Chain (ETC) Components in TM KO Mice 
 
BN-PAGE allowed for assessment of ETC complexes in their enzymatically active form. Therefore, we 
were able to investigate potential alterations in activity of complex I, II, IV and V by incubation with 
substrates specific for the respective ETC complex. Spectrophotometric analysis revealed no major 
changes of the mitochondria isolated from brain, heart and liver of TM KO and WT mice (Figure 19). 
The experiments were performed by Dr. Sven Dennerlein, Department of Cellular Biochemistry, PI 
Prof. Dr. Peter Rehling (according to Wittig et al., 2007; Deckers et al., 2014). In order to verify the 
mentioned unmodified CIV activity in the investigated 3 tissue types of TM KO mice, I investigated 
the enzyme activity by an alternative approach. To that end the CIV enzyme activity dipstick assay 
was performed on DRG dissected from both genotypes. It was composed of a specific antibody 
attached to a dipstick in combination with DAB as reporter of CIV activity (according to 
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manufacturer’s instruction). The mean pixel intensity of the precipitated DAB signal revealed 
comparable results between genotypes (Figure 20). 
 
Figure 19: ETC Activity Staining revealed no definite Difference among Genotypes 
Representative image showed the activity of ETC complexes I, II, IV and V. Mitochondria isolated from brain, 
heart, liver were fed with substrates for the mentioned complexes and activity levels were assessed 
spectrophotometrically. No overt changes could be detected compared between the genotypes. N = 2 mice; 2 
independent experiments. The experiments were performed by Dr. Sven Dennerlein, Department of Cellular 
Biochemistry, PI Prof. Dr. Peter Rehling. 
                 
Figure 20: Similar Complex IV Activity in TM KO Mice 
(A, B) Enzyme activity dipsticks for cytochrome c oxidase (COX, Complex IV) revealed no difference in DRG 
lysates of TM KO and WT mice. (A) Representative image of dipsticks from both genotypes. (B) The activity 
quantification (depicted as Pixel intensity) showed similar results. Number of animals in column; 3 independent 
experiments with DRG of 2 mice pooled from the same genotype; 3 technical replicates/ genotype/ 
experiment; unpaired student’s t-test. Data were represented as mean ± SEM. DRG, dorsal root ganglia. 
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3.1.8.3 Consistent Oxygen Consumption Rate Among Genotypes 
 
A commonly used approach to test for mitochondrial dysfunction is the determination of 
mitochondrial respiration by measuring the oxygen consumption rate (OCR) (Ferrick et al., 2008; 
Duggett et al., 2017). Pharmacological agents (Oligomycin: inhibits complex V, FCCP: ionophore 
which uncouples ATP synthesis from ETC function, Rotenone: inhibits complex I, Antimycin A: inhibits 
complex III (Duggett et al., 2017), KCN: inhibits complex IV (Puntel et al., 2013)) were utilized to 
modulate mitochondrial function to assess the bioenergetics profile. First, basal respiration was 
investigated by addition of substrates for complex II (Succinate) and complex IV (Ascorbate), 
followed by assessment of ATP-linked respiration and proton leak (Oligomycin), maximal respiratory 
capacity (FCCP) and reserve capacity (Antimycin A, Rotenone, KCN, respiratory ability to overcome 
stress) (Ferrick et al., 2008, Duggett et al., 2017). All investigated aspects of OCR were similar 
between genotypes (Figure 21). The experiments were performed by Dr. David Pacheu Grau, 
Department of Cellular Biochemistry, PI Prof. Dr. Peter Rehling. 
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Figure 21: Seahorse Experiments revealed unaltered Oxygen Consumption Rate in TM KO 
(A-F) OCR of isolated mitochondria from heart, brain and liver of TM KO and WT mice. (A, C, E) Similar OCR of 
mitochondria from heart, brain, and liver mitochondria after addition of Succinate (substrate for complex II) 
among genotypes. (B, D, F) Steady OCR from mitochondria of heart, brain, and liver from both genotypes after 
Ascorbate (substrate for complex IV) addition. Within each graph: A, calibration; B, substrate (basal 
respiration); C, Oligomycin (ATP-linked respiration + proton leak); D, FCCP (maximal respiratory capacity); E, 
Antimycin A + Rotenone + KCN (spare reserve capacity). N = 2-3 mice; 3 independent experiments; 2-way 
ANOVA followed by Sidak’s multiple comparison tests. Data were represented as mean ± SEM. The 
experiments were performed by Dr. David Pacheu Grau, Department of Cellular Biochemistry, PI Prof. Dr. Peter 
Rehling. OCR, oxygen consumption rate. 
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3.1.8.4 Similar Mitochondrial Membrane Potentials in DRG Culture of TM KO’s 
 
Alterations in mitochondrial membrane potential are generally associated with mitochondrial 
dysfunction, e.g. after chemical inhibition of ETC (Cannino et al., 2012). Therefore, I further tested for 
potential mitochondrial dysfunction after TM deletion by using the cell permeable dye TMRM 
(tetramethylrodamine, methyl ester) in DRG cultures (TM KO vs. WT). TMRM accumulated in 
mitochondria with intact membrane potential (major driving force for calcium uptake and proper ETC 
activity (Nicholls and Budd, 2000)) resulting in a strong signal. When the mitochondrial oxidative 
phosphorylation uncoupler FCCP was used to induce a membrane potential collapse the signal lost its 
strength as expected (Akude et al., 2011, Nicholls 2006). Using this approach, I studied potential 




Figure 22: TM KO DRG exhibited a normal Mitochondrial Membrane Potential 
(A-D) Course of TMRM imaging comprised of TMRM baseline, membrane potential collapse with FCCP and 
wash out with assay buffer. (A) Representative images for the TMRM signal, and two time points after FCCP 
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addition in DRG culture of both genotypes. (C) Pooled percentage of TMRM fluorescence intensity for the 
respective stimuli (each given for 2 minutes). (D) Imaging broken down into minutes revealing the time course 
of TMRM signal mitigation (min 1-2: TMRM; min 2-4 TMRM + FCCP; min 4-6 wash out with assay buffer). WT N 
= several coverslips from n = 3 independent cultures; KO N = several coverslips from n = 3 independent 
cultures; scale bar, 20 µm; 2-way ANOVA followed by Sidak’s multiple comparison tests. Data were represented 
as mean ± SEM. DRG, dorsal root ganglia. 
 
3.1.9 Oxidative Stress Response Compared Between Genotypes 
Malfunctioning mitochondria (e.g. due to altered ETC expression (Baloh et al., 2008; Fernyhough et 
al., 2010; Joseph et al., 2009; Osio et al., 2006)) have been shown to cause oxidative stress by 
increased ROS production (Kim et al., 2004). Given the investigated change in expression levels of 
ETC components (Figure 17 A), but not on protein level (Figure 18), I was interested in studying a 
potential difference in the oxidative stress response among genotypes. Therefore, mitochondrial ROS 
was assessed under naive conditions, as well as protein adduct formation due to oxidative stress 
under inflammatory pain conditions. These experiments revealed a slight increase in mitochondrial 
ROS in DRG cultures of TM KO mice. However, modified lipid peroxidation upon inflammatory pain 
could not be shown in DRG of both mouse lines upon CFA injection. 
3.1.9.1 Increased Mitochondrial ROS in DRG Culture of TM KO’s 
 
I investigated mitochondrial ROS by live-imaging of sensory neurons with Mitosox (mitochondrial 
ROS sensitive dye, which revealed a red color when oxidized) and measured its mean intensity in the 
soma. Furthermore, the percentage of Mitosox positive neurons was examined among genotypes. A 
minor increase in the mean Mitosox intensity was determined in somata of sensory neurons from 
naive TM KO mice. This result could indicate a slight augmentation in ROS production, which could be 
caused due to the shown differential expression of ETC components on mRNA level (Figure 17 A) 
(Hall et al., 2014; Willemen et al., 2018). However, no alteration of ETC subunits could be examined 
on protein level (Figure 18). As mentioned in the first results section (3.1.1), differential mRNA and 
protein levels were not surprising given the well-known limited correlation (Liu et al., 2016; 
Schwanhäusser et al., 2011; Sharma et al., 2015). Therefore, it can only be speculated that the 
differential mRNA levels were involved in the increased Mitosox intensity in TM KO sensory neurons. 
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Figure 23: Slightly increased Mitosox Signal in DRG of TM KO Mice 
(A) Representative image of DRG culture from both genotypes stained for Mitosox. (B) Fluorescence analysis 
revealed a slight increase of Mitosox in DRG of TM KO’s. (C) No alteration in percentage of neurons positive for 
the mitochondrial ROS marker. Number of cultures in column; several coverslips/ culture; scale bar, 50 µm; 
unpaired student’s t-test; * p < 0.05. Data were represented as mean ± SEM. DRG, dorsal root ganglia. 
3.1.9.2 Unmodified Lipid Peroxidation after TM Deletion 
 
Given the fact that the behavioral phenotype (3.1.5) was specific for inflammatory pain conditions, I 
investigated DRG from both genotypes after CFA injection. Therefore, immunohistochemistry was 
performed on cryo-embedded lDRG from TM KO and WT mice post CFA injection (24 h post CFA, ipsi 
and con lDRG). I examined oxidative stress among genotypes with a 4-HNE (4-hydroxy-2-nonenal)-
protein adduct antibody (Akude et al., 2010; Obrosova et al., 2007) and could not detect any 
differences in terms of 4-HNE fluorescence intensity (Figure 24). 
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Figure 24: Unchanged 4-HNE Intensity in TM-deficient CFA-treated Mice 
Fluorescence intensity of 4-HNE- protein adducts assessed in lDRG of mice (CFA injected paw: ipsi vs. non 
injected paw: con of both genotypes) revealed no difference. Number of animals in column; scale bar, 50 µm; 
1-way ANOVA followed by Sidak’s multiple comparison tests. Data were represented as mean of 7 analyzed 
images/ mouse ± SEM. lDRG, lumbar dorsal root ganglia; ipsi, ipsilateral; con, contralateral; CFA, Complete 
Freund’s Adjuvant. 
3.1.10 Altered Inflammatory Signaling Pathways in TM KO mice 
Painful conditions are correlated with numerous inflammatory signaling pathways. During 
inflammatory pain the “inflammatory soup” (inflammatory mediators) could lead to dysfunctional 
plasticity of the pain axis resulting in chronification (Woolf, 2007). Based on that knowledge and on 
our promising qRT-PCR results (3.1.7, Figure 17 B), which showed a significant decrease in TNFα 
levels in DRG of TM KO mice, I wanted to perform further assays in order to investigate inflammatory 
signaling. Ca2+-imaging results revealed a lower amount of TRPA1 expressing neurons in Veh treated 
cultures. Upon TNFα incubation the amount of TRPA1 responders could be compensated back to WT 
Veh levels. These results underscored the lower TNFα mRNA levels in DRG of TM KO mice as the 
inflammatory cytokine causes surface delivery of TRPA1 (Meng et al., 2016). 
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3.1.10.1 Equal CFA induced Macrophage Activation in TM KO DRG 
 
Microglia/ macrophages are activated by ROS (Kallenborn-Gerhardt et al., 2012), which results in the 
production and release of inflammatory mediators contributing to chronic pain (Clark and Malcangio, 
2014; Graeber and Christie, 2012; Milligan and Watkins, 2009; Old et al., 2015; Ren and Dubner, 
2010). Therefore, the amount of macrophages was evaluated by measuring the Iba1 (ionized 
calcium-binding adapter molecule 1) positive area in lDRG (isolated 24 h post CFA injection) 
normalized to the total tissue area. However, the experiment was not successful as the Iba1 area was 
not increased in the positive control (Iba1 should have been increased in lDRG ipsi of WT mice 
compared to lDRG con, Willemen et al., 2018). The trend for an increased Iba1 in lDRG ipsi of WT 
mice resulted from 1 of the 3 analyzed animals (7 analyzed images of several lDRG sections/ mouse, 
Figure 25). Therefore, the question if impaired macrophage activation was involved in the behavioral 
phenotype characterized by mitigated mechanical hypersensitivity during inflammatory pain, (1 and 
3 days post CFA injection, 3.1.5) remained open. The experiment will be performed in regard to 
microglia activation in the spinal cord of TM KO and WT mice 24h post CFA injection. 
 
Figure 25: Macrophage Staining in DRG of TM KO and WT Mice under Inflammatory Pain 
Conditions 
No difference in Iba1 area among lDRG con and ipsi of both genotypes after induction of inflammatory pain (24 
h post). Experiment was not successful, because positive control (Iba1 area should be increased in lDRG WT ipsi 
compared to lDRG WT con) failed. Number of animals in column; scale bar, 100 µm; 1-way ANOVA followed by 
Sidak’s multiple comparison tests. Data were represented as mean of 7 analyzed images of several DRG 
sections/ mouse ± SEM. Area of Iba1 signal (indicated by arrow heads) normalized to total lDRG area. Iba1, 
ionized calcium-binding adapter molecule 1; lDRG, lumbar dorsal root ganglia; ipsi, ipsilateral; con, 
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contralateral; CFA, Complete Freund’s Adjuvant. 
3.1.10.2 Differential TRPA1 dependent Calcium Signaling in TM KO’s  
 
Based on the decreased TNFα expression investigated in DRG of TM KO mice (mRNA level Figure 17 
B), I aimed to examine inflammatory signaling upon incubation with TNFα. DRG cultures from both 
genotypes were stimulated with TNFα or vehicle for 6 h followed by Ca2+-imaging in order to imitate 
inflammatory conditions (Willemen et al., 2018). It was shown that the prototypic inflammatory 
mediator evokes an increased Ca2+ influx via TRPV1 and TRPA1 due to an elevated surface delivery of 
those channel proteins (Meng et al., 2016). Based on that data, I was interested in studying calcium 
levels in cultured DRG from TM KO and WT mice by stimulation with mustard oil (30 µM MO, TRPA1 
agonist), capsaicin (100 nM Caps, TRPV1 agonist) and potassium chloride (60 mM KCl, neuronal 
activity). Interestingly, fewer TRPA1 expressing neurons were activated in DRG of TM KO’s (vehicle 
treated) compared to WT controls (vehicle treated). This lower amount of MO responders in TM KO 
DRG could be compensated by TNFα resulting in the same percentage of responders in WT (vehicle 
treated) and KO (TNFα treated). This effect was based on the significant increase of MO responding 
cells in TM KO after TNFα stimulation compared to vehicle stimulation. Furthermore, the capsaicin 
amplitude was increased in TM KO DRG after cytokine application. The lower percentage of MO 
responders in TM KO’s in vehicle treated cultures, which could be compensated with TNFα 
application (Figure 26) might explain the attenuated mechanical hypersensitivity assessed under 
inflammatory pain conditions in TM KO’s (3.1.5). Given TRPA1 involvement in inflammatory pain 
signaling (Dai et al., 2007; Meng et al., 2016; Schmidt et al., 2009; Wang et al., 2008) and mechanical 
hypersensitivity (Kwan et al., 2006; Petrus et al., 2007), it could be possible that the behavioral 
phenotype was based on the lower amount of TNFα expression, which leads to reduced TRPA1 
surface delivery (Meng et al., 2016). The experiments were performed by my Master student Hanna 
Kristina Fischer, taught and supervised by me. 
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Figure 26: TNFα Stimulation compensated lower Amount of TRPA1 Responders in TM KO Neurons 
(A-D) Representative traces (20 neurons) of response amplitudes (peak of fluorescence 340/380 above 
baseline) of (A) WT Veh, (B) WT TNFα, (C) KO Veh and (D) KO TNFα studied by ratiometric calcium imaging of 
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sensory neurons of WT and TM KO mice. 3 stimuli were given (30 µM MO, 100 nM Caps, 60 mM KCl) and 
resulting amplitudes were measured. (E) Lower WT TNFα mean amplitude compared to KO TNFα after 100 nM 
Caps stimulus, whereas no alterations were seen for other stimuli. Cell count in columns; WT N = several 
coverslips from n = 3 independent cultures; KO N = several coverslips from n = 3 independent cultures; 1-way 
ANOVA followed by Sidak’s multiple comparison tests; * p < 0.05. Data were represented as mean ± SEM. (F) 
Decreased proportion of MO responders in KO Veh compared to WT Veh. Incubation with the cytokine TNFα 
resulted in the adjustment of the previously lower amount of KO responders to a level with is similar to WT Veh 
during the MO pulse. This increase of responses specific for TRPA1 expressing neurons after TNFα stimulation 
in DRG of TM KO mice was significantly higher compared to KO Veh. No alterations for Caps or KCl responders. 
Colored area of stacked bar graphs showed proportion of responders (colored) and non-responders (white). 
Count of total number of neurons in columns; WT N = several coverslips from n = 3 independent cultures; KO N 
= several coverslips from n = 3 independent cultures; the Fisher exact test; * p < 0.05, ** p < 0.01.The 
experiments were conducted by my Master student Hanna Kristina Fischer, taught and supervised by me. DRG, 
dorsal root ganglia; MO, mustard oil; Caps, capsaicin; KCl, potassium chloride; Veh, Vehicle; TNFα, tumor 




















4.1 Characterization of TM as Novel Pain Modality-specific Mitochondrial 
Protein 
The specific mechanisms underlying persistent pain states remain to be fully understood. Here, I 
present a completely novel and important role for the hitherto uncharacterized mitochondrial 
transmembrane protein TM in inflammatory pain. The comprehensive proteome profiling study from 
Rouwette and colleagues revealed a downregulation of TM upon inflammatory and neuropathic pain 
conditions (Rouwette et al., 2016). Based on this finding, I investigated its functional role in 
somatosensation and pain in vivo. I showed that TM KO mice exhibit an impairment of mechanical 
hypersensitivity during inflammatory pain and early neuropathic pain (POD 7, when inflammation is 
most prominent (Cobos et al., 2018)). Strikingly, other investigated pain modalities (e.g. thermal 
hypersensitivity, non-evoked and movement-evoked pain) were unaltered upon TM deletion. While 
further work is needed to fully comprehend the mechanistic basis for the observed chronic pain 
phenotype in TM KO mice, there is strong evidence for altered inflammatory signaling pathways after 
TM ablation. Calcium imaging revealed a decreased activation of TRPA1 expressing neurons in DRG 
cultures of TM KO mice, which could be compensated by incubation with TNFα. These findings were 
in line with lower mRNA levels of the prototypic inflammatory mediator TNFα in DRG of naive TM KO 
mice. Furthermore, the chemokine CCl2, also known to be implicated in inflammatory pain signaling, 
was downregulated in sciatic nerves of TM KO’s. Additionally, TM depletion caused an alteration in 
the expression of several subunits of the mitochondrial electron transport chain as well as decreased 
levels of the mitochondrial transcription factor Tfam (mRNA level). However, alterations on protein 
level and further assays to test for mitochondrial dysfunction could not be detected. Moreover, 
major changes were not detected among genotypes regarding oxidative stress responses in naive TM 
KO mice and after induction of inflammatory pain. Altered neuronal excitability (naive TM KO mice) 
and expression (naive and CFA-treated TM KO mice) could not be identified as potential mechanism 
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4.1.1 No overt Mitochondrial Dysfunction upon TM Deletion 
Pain medication has a great potential for improvement, because the existing analgesics are 
inadequate as they are targeting molecules with important physiological functions resulting in strong 
side effects. However, the basis for the suboptimal treatment is the incomplete knowledge about the 
molecular mechanisms underlying chronic pain (Patapoutian et al., 2009). A major step forward was 
taken by performing unbiased quantitative proteome profiling (mass spectrometry) with DRG of mice 
exhibiting 2 pain entities, which revealed the differential regulation of known pain players as well as 
novel mediators (Rouwette et al., 2016). These results included the modulation of dozens of 
mitochondrial proteins. TM was identified among them and functionally investigated as it was 
scarcely characterized, had a differential regulation upon pain and revealed a high expression in DRG.  
I was able to proof its ubiquitous expression in mitochondria (Figure 6), which was particularly 
interesting given the evolving notion that diverse pathological pain conditions are accompanied by 
mitochondrial dysfunction (Baloh et al., 2008; Fernyhough et al., 2010; Joseph et al., 2009; Osio et al., 
2006; Rouwette et al., 2016). Impaired mitochondrial function can arise from oxidative stress 
induced by increased ROS production (Kim et al., 2004), which leads to microglia activation 
(Kallenborn-Gerhardt et al., 2012). Moreover, electron transport chain (ETC) activity changes (Baloh 
et al., 2008; Fernyhough et al., 2010; Joseph et al., 2009; Osio et al., 2006) and an unbalanced 
calcium homeostasis (Shishkin et al., 2002) are implicated in altered mitochondrial function. 
Therefore, I examined TM KO mice regarding potential changes in mitochondrial function and could 
identify the downregulation of the mitochondrial transcription factor A (Tfam) on mRNA level (Figure 
17 A) in DRG of naive TM KO mice. Tfam is a nuclear encoded mitochondrial protein, which is crucial 
for mitochondrial DNA (mtDNA) transcription and replication (Ekstrand et al., 2004; Larsson et al., 
1998). Reports have shown that mice with a tissue specific Tfam KO reveal a serious mtDNA 
deficiency and mitochondrial respiratory chain depletion (Larsson et al., 1998; Silva et al., 2000; 
Sörensen et al., 2001; Wang et al., 1999; Wredenberg et al., 2002). Moreover, Viader et al. claim that 
a mitochondrial dysfunction caused by a Schwann cell (SC) specific Tfam deletion in mice is sufficient 
to cause demyelination and axonal degeneration. Furthermore, mitochondria isolated from sciatic 
nerves of these Tfam KO’s revealed a decrease of Cox (Complex IV) activity by half and decreased 
mitochondrial respiration. These deficiencies might be caused by Complex I, III, IV defects as these 
incorporate mtDNA-encoded subunits (Viader et al., 2011). The decreased Tfam mRNA levels 
identified in DRG of naive TM KO mice in my study could therefore also explain the downregulation 
of Cox1 (cytochrome c oxydase c1 (Complex IV)) and ND2 (subunit of NADH dehydrogenase (Complex 
I)) given their mitochondrial encoding. However, the mitochondrial encoded subunit of Complex III 
(Cytb, cytochrome b) was not differentially expressed and the nuclear encoded Uqcr10 (ubiquinol-
cytochrome c reductase, complex III subunit X (Complex III)) was  upregulated in DRG of TM KO mice 
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(Figure 17 A). Since the composition of Complex III is based on mitochondrial and nuclear encoded 
proteins, I expected a decrease in Cytb mRNA levels as well upon Tfam reduction. However, this 
could be explained by the relatively mild decrease in Tfam expression which does not necessarily 
have to affect all subunits of the ETC in a similar manner. Additonally, I continued with the 
investigation of ETC components expression after the induction of inflammatory pain (1 d post CFA), 
showing no major changes in TM KO DRG and sciatic nerve. Furthermore, the altered ETC subunit 
expression under naive conditions seems to be compensated under inflammatory pain conditions, 
because no major differences among genotypes were identified (Figure 17). This finding indicates a 
different mechanistic basis for the attenuated mechanical hypersensitivity upon CFA injection in TM 
KO mice (3.1.5). Nevertheless, motivated by the differential expression under naive conditions, I 
intented to investigate further aspects of mitochondrial function. These included the study of 
mitochondrial protein expression (ETC subunits, Figure 18), activity levels of ETC components (Figure 
19, 20), oxygen consumption rate (Figure 21) and mitochondrial membrane potentials (Figure 22). 
Collectively, all of the mitochondrial function parameters were similar among genotypes. However, it 
is important to mention that the assays were either performed with DRG lysates/ cultures (Figure 20, 
22) or with mitochondria isolated from brain, heart, liver of naive mice from both genotypes (Figure 
18, 19, 21). Mitochondria from DRG were not used, as previous studies showed that DRG of 10 mice 
would be needed to extract enough of these organells. As the TM KO was constitutive, all tissues 
were affected making the use of brain, heart and liver informative after all. 
Furthermore, I examined whether TM deficiency in DRG affected the oxidative stress response. 
Based on the analgesic phenotype of TM KO mice and the implication of oxidative stress in distinct 
chronic pain pathologies, (Akude et al., 2011; Baloh et al., 2008; Flatters et al., 2015), I expected 
decreased ROS levels upon TM deletion. An additional guiding principle for this assumption was the 
nexus between oxidative stress and differential expression of ETC components leading to increased 
ROS production (Kim et al., 2004). I demonstrated the regulation of ETC subunits in DRG of TM KO 
mice on mRNA (Figure 17 A), but not on protein level (Figure 18). However, experiments assessing 
the amount of mitochondrial ROS (Mitosox used as indicator) revealed an opposite outcome. A slight 
increase in ROS levels was shown in DRG isolated from TM deficient mice (Figure 23). Given the 
moderate increase I do not assign a biological relevance to this outcome, which is also supported by 
intact mitochondrial function examined in naive TM KO mice. These findings correlate with 
unaffected basal somatosenstation (3.1.5, pretesting values). Nonetheless, to investigate whether 
mitochondrial dysfunction is the basis for the observed chronic pain phenotye in TM KO mice (3.1.5), 
the mentioned assays need to be performed with DRG/ mitochondria isolated from mice exhibiting 
chronic pain.  
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4.1.2 The Need for an extended Pain Paradigm Portfolio 
Rouwette et al. were able to identify dozens of novel chronic pain mediators by proteomics and 
functionally validated the biological significance of some candidate proteins in nociception and pain 
(Rouwette et al., 2016). This study is a crucial stepping stone for the determination of the molecular 
pain signature. However, a further hurdle for the identifcation of proper analgesics is the translation 
from animal studies to the clinic (Gregory et al., 2013). Criticizm is often addressed to pain models as 
they do not fully reflect clinically relevant pain entities like spontaneous pain (Cobos et al., 2012; 
Mogil et al., 2010; Urban et al., 2011). In fact, non-evoked pain at rest considered as spontaneous 
pain, is the pain entity often reported by chronic pain patients (Gottschalk and Ochroch, 2008; 
Maguire et al., 2006; Wildgaard et al., 2009). Thus, the first step for an improved translation into 
clinics might be the expansion of commonly used reflexive behavioral paradigms by non reflexive 
pain measurements (test for spontaneous pain) (Gregory et al., 2013). This is further emphasized by 
a study showing that measures of spontaneous pain correlated with altered dynamic gait parameters 
(movement-evoked pain) in the initial phase of neuropathic pain in the SNI model. Pitzer and 
colleagues also demonstrated that static gait parameters upon induction of neuropathic pain (SNI 
model) were timely congruent with stimulus-evoked pain behavior (mechanical and thermal 
hypersensitivity). These findings indicated the gait analysis as valuable tool to examine movement-
evoke pain in the SNI model (Pitzer et al., 2016). Based on the mentioned critizism and the findings 
from Pitzer et al. our collaboration partner Dr. Daniel Segelcke (Group of Translational Pain Research, 
PI Prof. Esther Pogatzki-Zahn) implemented non reflexive parameters (non-evoked pain and 
movement-evoked pain) in the functional investigation of TM in vivo. The broad behavioral 
investigation of TM KO mice revealed a modality-specific phenotype under inflammatory pain 
conditions (CFA injection, 3.1.5). More precisely, TM KO mice showed attenuated mechanical 
hypersensitivity at day 1 and 3 post CFA injection as well as in the initial phase of neuropathic pain 
(POD 7), where inflammation is most prominent (Cobos et al., 2018). These results indicate that TM 
is a pro-algesic factor specifically involved in the stimulus-evoked mechanical pain hypersensitivity. 
Further behavioral investigation of mice harboring a sensory neuron specific TM KO showed a similar 
phenotype suggesting a sensory neuron specific TM contribution. Non reflexive parameters like non-
evoked pain and movement-evoked pain are not altered among genotypes after chronic pain 
induction. Therefore, TM is proposed to be implicated in mechanical stimulus evoked- but not 
spontaneous pain. This could be explained by different mechanisms underlying evoked and 
spontaneous pain (Hung et al., 2016; Mogil et al., 2010). This specific involvement of TM in chronic 
pain underscored the importance for the performance of a wide range of behavioral paradigms to 
pinpoint the mechanistic basis for potential pain mediators. Our results are in line with findings from 
Pitzer et al. (Pitzer et al., 2016). However, it is important to mention that altered gait parameters 
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during chronic pain are controversially debated. Mogil et al. claim that gait changes do not correlate 
with pain (Mogil et al., 2010), whereas others suggest that a correlation exists (Coulthard et al., 2002; 
Möller et al., 2012; Parvathy and Masocha, 2013; Piesla et al., 2009). The basis for differential 
findings could be diverse mouse strains, the investigated pain model as well as the time point of 
investigation and the test chosen for the examination (Pitzer et al., 2016). It was argued that 
inflammatory pain per se causes altered gait in inflammatory pain models (Piesla et al., 2009), while 
the gait impairment during neuropathic pain is assigned to motor system malfunction (Piesla et al., 
2009). On the other hand, it was shown that motor impairment was not the basis for gait alteration 
during neuropathic pain (Deumens et al., 2007; Vrinten and Hamers, 2003). Moreover, chronic pain is 
a complex and multidimensional disease involving affective and emotional elements as well as the 
general well-being (Melzack and Casey, 1968; Twillman, 2007). Given that, a promising approach 
would be to extend the battery of behavioral tests even further in future studies examining these 
components to get a more thourough picture of pain (Pitzer et al., 2016).  
 
4.1.3 Decreased Neuronal Subpopulation Excitability after TM Elimination 
Calcium-permeable TRP (transient receptor potential) channels like TRPV1 and TRPA1 are highly 
expressed in nociceptors. They are mainly implicated in the transduction of noxious stimuli and 
modulation of nociceptive processing (Bourinet et al., 2014; Patapoutian et al., 2009). Their 
activation is involved in physiological and pathophysiological pain signaling based on their regulation 
and sensitization (Caterina et al., 1997, 2000; Obata et al., 2005; Sousa-Valente et al., 2014; Story et 
al., 2003). Furthermore, Piezo2 ion channels play crucial roles in vertebrate light touch (Coste et al., 
2010, 2012; Ranade et al., 2014). Given the important roles of the mentioned ion channels, I wanted 
to examine whether their neuronal activity was altered in TM depleted mice. Therefore, 
electrophysiology was performed in addition to ratiometric calcium imaging. More precisely, Ca2+-
imaging was carried out by application of specific chemical stimuli to activate the TRP channels 
(capsaicin: TRPV1 agonist (Caterina et al., 1997); mustard oil: TRPA1 agonist (Bautista et al., 2006; 
Jordt et al., 2004)). The experiments indicated decreased mustard oil-evoked calcium responses upon 
TM elimination (Figure 26 A, KO Vehicle), whereas the capsaicin dependent calcium influx was 
unaltered (Figure 16 and Figure 26, KO Veh). Besides, Piezo2-mediated mechanotransduction (Coste 
et al., 2010, 2012; Ranade et al., 2014) was not affected in naive TM KO mice (Figure 15). These in 
vitro findings were in line with the unaltered basal sensitivity of TM KO mice to thermal (TRPV1 
involvement, Caterina et al., 1997; Julius, 2013) and mechanical (Piezo2 mediated, Coste et al., 2010, 
2012; Ranade et al., 2014) paw stimulation (pretesting values) as well as nocifensive behavior upon 
intraplantar capsaicin (TRPV1 mediated acute pain, Caterina et al., 2000) injection (3.1.5). Whether 
mustard oil induced acute pain behavior (Bautista et al., 2006; Kwan et al., 2006) correlates to the 
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reduced levels of TRPA1 mediated calcium influx (Figure 26 A, KO Veh) needs to be determined in 
future experiments.  
 
All together, the results suggest that TM elimination does not affect basal somatosensation and 
capsaicin induced physiological pain but rather advocate for the described implication in chronic 
pain.  
 
4.1.4 Modulatory Role for TM in Inflammatory Pain Signaling 
It was noticeable that TM depletion alleviated only mechanical hypersensitivity during inflammatory 
pain and the initial stage of neuropathic pain (POD 7), while thermal sensation was unaffected 
(3.1.5). This modality-specific TM involvement might be based on a functional connection to the 
immune system. This hypothesis is supported by decreased mRNA levels of the prototypic 
inflammatory mediators TNFα (tumor necrosis factor alpha, Figure 17 B) and CCl2 (chemokine (C-C 
motif) ligand 2, Figure 17 D) in DRG or sciatic nerves of naive TM KO mice. However, the 
downregulation of these inflammatory markers could not be shown after CFA injection (Figure 17 G, 
H), which could be explained by a high sample variability that might underrepresent an effect. 
Furthermore, Cobos et al. showed the linkage of immune cells and neurons to mechanical 
hypersensitivity (tactile allodynia) and mainly neurons to thermal hypersensitivity (cold allodynia) 
upon neuropathic pain (SNI model). They demontrated that cold allodynia develops relatively fast 
having its peak at POD 4-5, whereas tactile allodynia reveals a slower progression with maximal 
hypersensitivity at POD 7-8 (Cobos et al., 2018). This finding is in line with other studies showing a 
slower course of mechanical hypersensitivity compared to cold allodynia (Decosterd and Woolf, 
2000; Pertin et al., 2007; Wijnvoord et al., 2010). Interestingly, POD 7 defined by maximal tactile 
allodynia post SNI, was the exact time point where TM KO mice revealed an impairment in this pain 
modality (3.1.5). Motivated by the different starting points of mechanical and cold allodynia Cobos et 
al. performed transcriptomics (ipsilateral DRG post SNI, daily until POD 10) in order to correlate the 
relative timing of gene expression with the evoked pain behavior (Cobos et al., 2018). Intriguingly, 
the onset of cold allodynia nicely corresponded to early neuronal gene regulation as well as 
mechanical allodynia which correlated to the differential expression of immune cell related genes 
(Cobos et al., 2018). The immune cell genes seemed to be enriched in macrophages and T cells 
known to be abundant in DRG after nerve damage (Hu and McLachlan, 2002; Moalem and Tracey, 
2006). Moreover, Trpv1-deficient mice (to a great part insensitive to temperature as TRPV1 is an 
early developmental marker of all cold- and hot neuronal detectors, (Mishra et al., 2011)) revealed 
impaired cold hypersensitivity after SNI, while tactile allodynia was present. On the other hand, 
macrophage or T cell-depleted mice, showed alleviated mechanical hypersensitivity and unimpaired 
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cold allodynia post SNI. These findings suggest a distinct cellular and molecular mechanism necessary 
for the induction of cold and tactile allodynia upon nerve injury (Cobos et al., 2018). The basis for 
cold allodynia might be paracrine signaling from injured DRG neurons which alter the sensitivity of 
neighboring intact thermo-nociceptors to cold or abnormal processing in the central nervous system 
(CNS). The ectopical activity of injured C-nociceptors (Kirillova et al., 2011) could support central 
sensitization leading to painful perception of low-threshold thermoreceptor inputs into the dorsal 
horn (Latremoliere and Woolf, 2009). Contrarily, tactile allodynia seems to be evoked by low-
threshold mechanoreceptors (LTMRs) (Campbell and Meyer, 2006; Xu et al., 2015) of which a broad 
range expresses Piezo2 relevant for touch sensation (Ranade et al., 2014), and activated immune 
cells (Cobos et al., 2018). These cells might trigger the phenotypic switch of A-fibers after nerve 
injury which thereby gain the capacity to initiate central sensitization. Another possibility could be 
the sensitization of intact high-threshold A-fiber nociceptors by immune cells upon PNS damage. The 
basis for mechanical allodynia could be either of these mechanisms or a combination of both (Cobos 
et al., 2018). This study from Cobos and colleagues highly supported my hypothesis for the specific 
contribution of TM in immune signaling. I showed that TNFα and CCl2 mRNA was downregulated in 
naive TM KO mice (Figure 17). These inflammatory mediators are known to be secreated from 
immune cells like macrophages upon nerve injury (accompanied by inflammation) contributing to 
hypersensitivity (Andrade et al., 2014; Schuh et al., 2014; Zhu et al., 2014). However, as mentioned 
above a reduction of these signaling molecules could not be demonstrated upon inflammatory pain 
as samples revealed a high variability. The reduction under naive conditions might indicate a slightly 
suppressed immune system that manifests as behavioral outcome only when challenged by the 
induction of inflammatory pain. Furthermore, interferon-gamma (IFN-g) secreted by Th1 T cells can 
lead to macrophage attraction to inflamed tissue and cause pain (Liou et al., 2011). On the other 
hand, type 2 inflammatory cytokines (e.g. TGF-b, IL-10, IL-4) can alleviate neuropathic pain-like 
behavior (Chen et al., 2015; Dengler et al., 2014; Kiguchi et al., 2015). Yet, the role of T cells in 
neuropathic pain conditions has been investigated in several studies with controversial outcomes. 
Some did not correlate T cell action to the pain- phenotype (Sorge et al., 2015), while others where 
able to show the connection (Cao and Deleo, 2008; Cobos et al., 2018; Costigan et al., 2009a; 
Kobayashi et al., 2015; Leger et al., 2011; Zhang et al., 2014). This divergency might originate from 
the balance between the mentioned pro-and anti-inflammatory subdivisions in distinct experimental 
settings (Austin et al., 2012; Kiguchi et al., 2015). Moreover, all studies were performed with male 
rodents except for Sorge and colleagues, who investigated both sexes. Sorge et al. showed that 
mechanical hypersensitivity during inflammatory and neuropathic pain was microglia-mediated in 
male and based on adaptive immune cells (probably T cells) in female mice (Sorge et al., 2015). This 
finding could be approved by another study suggesting that T cells mediate pain hypersensitivity in 
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female mice (Mapplebeck et al., 2016). Interestingly, my study revealed that the sensory neuron 
specific (cKO in SeN) TM KO mice showed a similar attenuation of mechanical hypersensitivity upon 
CFA injection as constitutive KO mice (3.1.5.). Even though half of the investigated cKO in SeN mice 
were females, mainly TM KO males were tested. This similar outcome among sexes might indicate 
alterations in immune signaling in both KO lines which cannot specifically be associated to 
macrophages or T cells. As Cobos et al. proposed that it could be an interaction of both immune cells 
leading to alterations within the DRG that cause tactile allodynia. However, the underlying 
mechanism needs to be further investigated (Cobos et al., 2018). Given the involvement of 
macrophages in mechanical hypersensitivity, I investigated the amount of these cells within the DRG 
of male TM KO and WT mice upon induction of inflammatory pain (1 d post CFA). Unfortunately, the 
experiment was not successful as WT DRG isolated from the CFA-injected body part did not reveal an 
increased amount of macrophages compared to the contralateral side. Therefore, it is not possible to 
conclude whether the unaltered level of macrophages in TM KO DRG (ipsi vs. con) was reliable. 
Furthermore, it will be important to assess potential alterations of T cells in DRG as well as microglia 
levels within the spinal cord in order to advance towards the understanding of the mechanism which 
underlies impaired mechanical hypersensitivity during inflammatory and early neuropathic pain. 
Cobos et al. stated that macrophages and T cells most probably act on sensory fibers which do not 
belong to the TRPV1 lineage (Cobos et al., 2018). However, uninjured TRPA1 expressing high-
threshold A-fiber nociceptors might be sensitized by these immune cells. Several studies claim TRPA1 
involvement in the development and preservation of hypersensitivity in diverse animal pain models. 
A definite mitigation of mechanical hypersensitivity was shown in inflammatory pain models due to 
TRPA1 antagonists or TRPA1 deficiency. Inflammation was either induced by TNFα, CFA or 
monoiodoacetate injection (Fernandes et al., 2011; Laing and Dhaka, 2016; McGaraughty et al., 
2010). Moreover, decreased cold and mechanical hypersensitivity was also reported upon 
neuropathic pain due to pharmacological inhibition or genetic TRPA1 ablation (Nassini et al., 2014). 
In addition, TRPA1 channels are targeted by inflammatory molecules and act as molecular oxidative 
stress sensors. One example is ROS, which levels severely increase upon tissue damage/ 
inflammation and can cause the induction of lipid peroxidation (Bautista et al., 2013). Thereby, 
diverse lipid peroxidation products (e.g. 4-oxononenal (4-ONE) and 4-hydroxynonenal (4-HNE)) were 
generated that can activate TRPA1 channels (Taylor-Clark et al., 2008; Trevisani et al., 2007). Given 
the implication of oxidative stress in inflammatory pain and the involvement of TRPA1, I wanted to 
investigate whether 4-HNE levels were altered in DRG from CFA injected TM KO and WT mice. 
However, I could not detect any differences among genotypes (Figure 24). These results were in line 
with Ca2+-imaging results upon TNFα stimulation which revealed unaltered TRPA1- and TRPV1-
mediated calcium responses (Figure 26). On the other hand, responses to mustard oil (MO) 
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application were reduced in Veh-treated TM KO mice which were compensated to WT Veh levels 
after stimulation with TNFα. These results underscored the reduced TNFα mRNA levels investigated 
in naive TM KO mice (Figure 17 B). Previous studies revealed that the basis for enhanced TRPV1-and 
TRPA1-mediated Ca2+ influx might be the increased surface delivery of these channels triggered by 
the prototypic inflammatory mediator TNFα (Meng et al., 2016). Intriguingly, all mentioned 
alterations in TM KO mice were investigated under naive conditions. These findings indicate a 
protective mechanism in regard to inflammatory pain susceptibility in TM deficient mice. In sum, 
there is evidence that this altered inflammatory signaling has its basis in decreased TNFα levels 
investigated in DRG of naive TM KO mice.  
 
4.1.5 Conclusion and Outlook  
Motivated by the significantly decreased TNFα mRNA levels in DRG of naive TM KO mice (Figure 17 
B), I wanted to obtain a vast overview of inflammatory mediators in the KO mice of interest. To this 
end, cytokine proteome profiling for 40 cytokines (CXCL13, C5a, G-CSF, GM-CSF, CCL1, CCL11, sICAM-
1, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-13, IL-12p70, IL-16, IL-17, IL-23, IL-
27, IP- 10, CXCL11, KC, M-CSF, CCL2, CCL12, CXCL9, CCL3, CCL4, CXCL2, CCL5, CXCL12, CCL17, TIMP-1, 
TNF-α and TREM-1) in DRG lysates from both mouse lines has been performed by my Master student 
Hanna Kristina Fischer, supervised and taught by me. The cytokine array allows for detection of all 
mentioned cytokines by incubation of protein lysates with antibody-coated membranes (according to 
Keskinov et al., 2016). The comparison of resulting cytokine spot intensities revealed a first trend 
(data not shown) for an overall reduction in DRG lysates of TM KO mice compared to WT mice. This 
potential dampened cytokine expression upon TM ablation needs to be verified by experimental 
repetitions. The trend for reduced cytokine levels is in line with the mentioned modifications in naive 
TM KO mice. However, the experiments will be additionally carried out upon induction of 
inflammatory and neuropathic (DRG isolation at POD 7) pain in order to investigate potential changes 
of inflammatory signaling during chronic pain. Among these cytokines were TNFα as well as GM-CSF 
(Granulocyte-macrophage colony-stimulating factor) and CCl17 (Chemokine (C-C motif) ligand 17) 
proposed to be implicated in the inflammatory and algesic action of TNFα (Cook et al., 2018). Based 
on these findings and the trend for a reduction of TNFα, GM-CSF and CCl17 on protein level in DRG 
lysates of TM KO mice, we will further proceed in this direction in order to identify the molecular 
mechanisms of the attenuated pain phenotype upon TM ablation. If the trend can be verified with 
DRG from additional TM KO mice, calcium imaging could be performed with sensory neurons of both 
genotypes being stimulated with GM-CSF and CCl17. qRT-PCR will also be performed to investigate a 
potential alteration of these cytokines on mRNA level. Furthermore, it is known that TNFα triggers 
ROS formation (Valko et al., 2007) and our qRT-PCR data showed a significant downregulation of the 
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prototypic inflammatory mediator in DRG of naive TM KO mice (Figure 17 B). Given that, I postulate 
lower ROS levels in DRG of TM KO mice after TNFα stimulation. So far the mitochondrial ROS 
indicator revealed a slightly increased intensity in DRG cultures of naive TM KO mice (Figure 23) and 
lipid peroxidation was unaltered upon CFA injection in DRG among both genotypes (Figure 24). 
However, in order to valdiate the hypothesis, the assessment of oxidative stress by the ROS-sensitive 
DHE (dihydroethidium)-dye is in progress. Cultured sensory neurons were stimulated for 6 h with 
TNFα (Hall et al., 2014; Hervera et al., 2018; Willemen et al., 2018) followed by DHE imaging and 
analysis (performed by my Master student Hanna Kristina Fischer, taught and supervised by me). In 
future experiments inflammatory pain will be induced by intraplantar injection of TNFα (Fernandes 
et al., 2011) in order to investigate whether decreased endogenous levels result in decreased pain 
behavior in TM KO mice. Moreover, TM KO and WT mice will additionally be injected in one of the 
hind paws with mustard oil (MO) in order to examine whether the acute pain behavior (Bautista et 
al., 2006; Kwan et al., 2006) is connected to the lower amount of TRPA1 mediated calcium responses 
in DRG of TM KO mice (Figure 26). The outcome can be valuable, given the implication of TRPA1 in 
mechanical hypersensitivity upon inflammatory pain (Fernandes et al., 2011; Laing and Dhaka, 2015; 
McGaraughty et al., 2010). In addition, TM will be re-expressed in TM KO mice by standard 
nucleofection in vitro and by virus-mediated gene transfer in vivo. Virus-mediated gene transfer was 
already successfully performed in our lab by sciatic nerve injections leading to transduction of 
sensory neurons of DRG in mice (Sondermann et al., 2018). Upon re-expression in vivo, behavioral 
paradigms will be performed in order to test whether the observed attenuated mechanical 
hypersensitivity upon inflammatory pain can be “rescued”. If the “rescue-experiment” was 
successful, it would underscore the essential role of TM downregulation per se to attenuate 
inflammatory mechanical hypersensitivity. These results would additionally support the hypothesis 
that the downregulation of TM serves as modality specific analgesic mechanism.  
I could show that the decreased TRPA1 dependent calcium influx in DRG of TM KO mice was 
equalized to WT levels upon stimulation with TNFα (Figure 26). This stimulation mimicked 
inflammatory conditions. However, the behavioral phenotype in TM KO mice was identified upon 
CFA injection (1 day post). Therefore, calcium imaging will also be carried out with DRG isolated from 
mice 1 day post CFA injection (with the same stimuli as given upon TNFα/ Veh stimulation (Figure 
26)). Neuronal acitivity (30 mM KCl) as well as TRPV1- (100 nM Caps) and TRPA1-mediated (30 µM 
MO) nociceptive signaling will be compared among genotypes. These DRG cultures prepared from 
CFA injected mice will also be subjected to electrophysiological experiments. In this way Piezo2-
mediated mechanotransduction in DRG cultures during inflammatory pain might give more insights 
about the mechanism underlying the phenotype investigated in TM KO mice. Piezo2 is crucially 
implicated in light touch and a role in tactile hypersensitivity during inflammatory and neuropathic 
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pain was shown. It was reported that inflammatory mediators can have a modulatory effect on 
Piezo2 (Dubin et al., 2012; Prato et al., 2017). Given those findings it might be possible that Piezo2 
alterations contribute to the investigated behavioral phenotype of TM KO mice. However, Piezo2 KO 
mice showed basal touch sensitivity in addition to tactile hypersensitivity upon capsaicin-induced 
inflammation. These findings are not in line with the behavior demonstrated by TM KO mice. 
Therefore, an exclusive role for Piezo2 is not supposed. All mentioned experiments will also be 
performed with DRG isolated from SNI-mice at POD 7, which is the time point at which reduced 
mechanical hypersensitivity was detected in TM KO mice (3.1.5). 
Collectively, we were able to characterize TM as a modality-specific contributor of inflammatory pain 
signaling. Its downregulation in DRG of mice exhibiting inflammatory and neuropathic pain 
(proteome profiling, Rouwette et al., 2016) could be identified as part of an analgesic system. A 
detailed behavioral analysis of chronic pain conditons by reflexive and non-reflexive paradigms 
accompanied by a wide variety of in vitro techniques enabled this approach. For future studies it 
would be promising to implicate a broadened pain paradigm portfolio standardized within the pain 
field in order to achieve an improved understanding of chronic pain mechanisms. Our findings 
underscored the importance for the identification of distinct mechanistic etiologies for thermal and 
mechanical hypersensitivity. In terms of tactile allodynia immune cells or mechanoreceptors negative 
for TPRV1 should be targeted. Therefore, the medication of patients suffering from either type of 
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Thesis: „Exploring the Function of a Novel Chronic Pain Player“ (Supervisor: 
Prof. Dr. Manuela Schmidt) 
Intended Degree: Dr. rer. nat. (expected June 2019) 
 
10/2013-05/2015 MASTER’S PROGRAM „DEVELOPMENTAL, NEURAL AND BEHAVIORAL 
BIOLOGY“ 
Georg-August-University Göttingen, Germany 
Thesis: „Analysis of Tg4-42 Mice with Regard to Memory Deficits and Gene 
Expression“ (Supervisor: Prof. Dr. Oliver Wirths, Grade: 1.8) 
Degree: Master of Science, Overall Grade: 1.8 
 
10/2009-09/2013  BACHELOR’S PROGRAM „BIOLOGY“ 
Georg-August-University Göttingen, Germany 
Thesis: „EPO Effects on the Oligodendrocyte Differentiation in the NG2-
CreERT2:R26R-td-tomato-mEGFP Mouse Model“ (Supervisor: Prof. Dr. Dr. 
Hannelore Ehrenreich, Grade: 1.3) 
Degree: Bachelor of Science, Overall Grade: 2.3 
 
06/2009    HIGH-SCHOOL DIPLOMA 
Paul-Gerhardt-School, Dassel, Germany  
MEMBERSHIPS AND STIPENDS 
11/2015 to date                                  Graduate School GGNB (Göttingen Graduate School for Neurosciences, 
Biophysics and Molecular Biosciences) 
 
01/2017-01/2018                               GGNB Junior Group Stipend 
 
09/2018                                                GGNB Travel Grant for the Poster  
„Mitochondrial Dysfunction in Chronic Pain-New Insights from 
Uncharacterized Mitochondrial Proteins“ (World Congress on Pain 2018, 
Boston) 
 
10/2017                                                GGNB Travel Grant for the Poster  
„Proteomics-ein vielversprechender Weg zur Charakterisierung  
neuer „Schmerzkandidaten““ (German Pain Congress 2017,  
Mannheim, Germany)  
PERSONAL SKILLS AND QUALIFICATIONS 
Languages                                            German (Mother Tongue), English (Proficient User), Spanish (Basic User) 
  
Computer Skills   Microsoft Office Tools, Graph Pad Prism, Image J 
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Additional Qualifications GMP Course-Good Manufacturing Practice (18/09/2017-22/09/2017) 
 
Göttingen, April 2019 
LIST OF PUBLICATIONS 
Original Articles 
Mtmr2 and PI(3,5)P2 interdependently control Piezo2-mediated mechanotransduction in peripheral sensory 
neurons. Narayanan P, Hütte M, Kudryasheva G, Francisco T, Lechner S, Rehlfelft F, Gomez-Varela D, Schmidt 
M. eLife 2018;7:e32346 doi: 10.7554/eLife.32346.   
Publication about PhD Project will follow. 
 
 
